<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Integr. Neurosci.</journal-id>
<journal-title>Frontiers in Integrative Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Integr. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5145</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnint.2023.1275794</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Hypothesis and Theory</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Autosomal recessive cerebellar ataxias: a diagnostic classification approach according to ocular features</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lopergolo</surname>
<given-names>Diego</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1382584/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosini</surname>
<given-names>Francesca</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/422214/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pretegiani</surname>
<given-names>Elena</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bargagli</surname>
<given-names>Alessia</given-names>
</name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1017327/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Serchi</surname>
<given-names>Valeria</given-names>
</name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/500513/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rufa</surname>
<given-names>Alessandra</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/20030/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Medicine, Surgery and Neurosciences, University of Siena</institution>, <addr-line>Siena</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>UOC Neurologia e Malattie Neurometaboliche, Azienda Ospedaliero-Universitaria Senese</institution>, <addr-line>Siena</addr-line>, <country>Italy</country></aff>
<aff id="aff3"><sup>3</sup><institution>UOC Stroke Unit, Department of Emergenza-Urgenza, Azienda Ospedaliero-Universitaria Senese</institution>, <addr-line>Siena</addr-line>, <country>Italy</country></aff>
<aff id="aff4"><sup>4</sup><institution>Unit of Neurology, Centre Hospitalier Universitaire Vaudoise Lausanne, Unit of Neurology and Cognitive Neurorehabilitation, Universitary Hospital of Fribourg</institution>, <addr-line>Fribourg</addr-line>, <country>Switzerland</country></aff>
<aff id="aff5"><sup>5</sup><institution>Evalab-Neurosense, Department of Medicine Surgery and Neuroscience, University of Siena</institution>, <addr-line>Siena</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn id="fn0001" fn-type="edited-by"><p>Edited by: Reza Rastmanesh, American Physical Society, United States</p></fn>
<fn id="fn0002" fn-type="edited-by"><p>Reviewed by: Helio A. G. Teive, Federal University of Paran&#x00E1;, Brazil</p>
<p>Christiane Susanne Hampe, University of Washington, United States</p></fn>
<corresp id="c001">&#x002A;Correspondence: Alessandra Rufa, <email>rufa@unisi.it</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>02</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>17</volume>
<elocation-id>1275794</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>08</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Lopergolo, Rosini, Pretegiani, Bargagli, Serchi and Rufa.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Lopergolo, Rosini, Pretegiani, Bargagli, Serchi and Rufa</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Autosomal recessive cerebellar ataxias (ARCAs) are a heterogeneous group of neurodegenerative disorders affecting primarily the cerebellum and/or its afferent tracts, often accompanied by damage of other neurological or extra-neurological systems. Due to the overlap of clinical presentation among ARCAs and the variety of hereditary, acquired, and reversible etiologies that can determine cerebellar dysfunction, the differential diagnosis is challenging, but also urgent considering the ongoing development of promising target therapies. The examination of afferent and efferent visual system may provide neurophysiological and structural information related to cerebellar dysfunction and neurodegeneration thus allowing a possible diagnostic classification approach according to ocular features. While optic coherence tomography (OCT) is applied for the parametrization of the optic nerve and macular area, the eye movements analysis relies on a wide range of eye-tracker devices and the application of machine-learning techniques. We discuss the results of clinical and eye-tracking oculomotor examination, the OCT findings and some advancing of computer science in ARCAs thus providing evidence sustaining the identification of robust eye parameters as possible markers of ARCAs.</p>
</abstract>
<kwd-group>
<kwd>autosomal recessive cerebellar ataxias</kwd>
<kwd>optical coherence tomography</kwd>
<kwd>eye-tracking</kwd>
<kwd>eye movements</kwd>
<kwd>artificial intelligence</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="149"/>
<page-count count="17"/>
<word-count count="13235"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<title>Introduction</title>
<p>Autosomal recessive cerebellar ataxias (ARCAs) are a heterogeneous group of neurodegenerative disorders affecting primarily the cerebellum and/or its afferent tracts. ARCAs are often accompanied by damage of other neurological (e.g., corticospinal tracts, basal ganglia, vestibular and visual sensory systems, and peripheral nerves) or extra-neurological systems (e.g., muscle, heart, gastrointestinal tract, glands <xref ref-type="bibr" rid="ref110">Rossi et al., 2018</xref>).</p>
<p>However, a variety of hereditary, acquired, and reversible etiologies can cause cerebellar dysfunction, leading to ataxia symptoms (<xref ref-type="bibr" rid="ref8">Beaudin et al., 2019</xref>). Thus, to date, the diagnosis of ARCAs remains challenging, particularly in adult-onset sporadic cases. Remarkable advances have been achieved during the least decades in the molecular and pathologic characterization of mechanisms underlying ARCAs, opening up new unexpected diagnostic and therapeutic perspectives (<xref ref-type="bibr" rid="ref113">Salem et al., 2023</xref>). Indeed, promising target therapies for some ataxias are at advanced development stages and the identification of quantitative markers of cerebellar function has become fundamental for a deep phenotyping and to precisely define possible outcome measures in clinical trials.</p>
<p>The examination of the afferent (retinal nerve fiber layer, ganglion cells) and efferent (fixation, saccades, pursuit, VOR) visual systems may represent a relevant source of neurophysiological and structural findings to study cerebellar dysfunction and neurodegeneration in ARCAs. This is well underlined by a recent consensus paper indicating that the study of eye movements is highly capable of localizing the anatomical lesion and is useful for the diagnosis and follow-up of patients (<xref ref-type="bibr" rid="ref54">Garces et al., 2023</xref>). In this respect, various classes of eye movements have been associated to specific anatomic and functional regions of the cerebellum, as well as neural networks between these regions and extracerebellar regions (<xref ref-type="bibr" rid="ref76">Leigh and Zee, 2015</xref>; <xref ref-type="fig" rid="fig1">Figures 1</xref>, <xref ref-type="fig" rid="fig2">2</xref>). Moreover, the diffusion of new, low cost, low impact and easy to use eye trackers together with the application of machine learning techniques supported by Artificial Intelligence (AI) simplified the study of the oculomotor system (<xref ref-type="bibr" rid="ref126">Stoean et al., 2020</xref>; <xref ref-type="bibr" rid="ref78">Li et al., 2021</xref>). Collecting big oculomotor data from many cerebellar patients, would lead to the identification of a few specific oculo-motor indicators of cerebellar and extracerebellar functions (<xref ref-type="bibr" rid="ref27">Cole et al., 2021</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption><p>Eye movements dysfunction and genetic disorders associated to specific cerebellar areas. On the left, we reported the association between the dysfunction of vermis, hemisphere and flocculonodular lobe and the relative eye movements impairment. On the right, cerebellar regions whose dysfunctions are mostly associated with the genetic disorders indicated in red. FRDA, Freiderich&#x2019;s ataxia; SPG7, Spastic Paraplegia 7; ARSACS, Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay; AT, Ataxia-Teleangiectasia; ATLD, ataxia-teleangiectasia like disorder; AOA1, ataxia with oculomotor Apraxia type 1; AOA2, Ataxia with Oculomotor Apraxia type 2; CTX, Cerebrotendinous Xanthomatosis; NPC, Nieman-Pick disease type C; AVED, ataxia with Vitamin E deficiency; COQ10D4, Coenzyme Q10 deficiency-4.</p></caption>
<graphic xlink:href="fnint-17-1275794-g001.tif"/>
</fig>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption><p>Eye movements in different cerebellar diseases recorded at EVA-Neurosense Lab (University of Siena). The prevalent oculomotor finding of each disease is associated to the mainly affected cerebellar region. ARSACS: VGS, hypometric vertical (8&#x00B0;) visually guided saccades, due to involvement of the oculomotor vermis. Gaze evoked ny is also evident, suggesting a loss of cerebellar neural integrator. AOA2: VGS, increased latency and multistep pattern of horizontal visually guided saccades (18&#x00B0;) due to hemispheric involvement. ATLD: VGS, dysmetric horizontal visually guided saccades (10&#x00B0;; undershooting and overshooting the target), first panel; ATLD Ny, rebound ny, second panel; ATLD: saccadic intrusion (SI), different amplitude and shape of high frequency saccadic intrusions, third panel. CTX AS, erroneous antisaccades (the movement is erroneously performed in the direction of the target instead in the opposite direction) saccades are hypometric. Axis: vertical (Y) indicates eye position in degrees; horizontal (X) indicates time in ms. FRDA, Freiderich&#x2019;s ataxia; SPG7, Spastic Paraplegia 7; ARSACS, Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay; AT, Ataxia-Teleangiectasia; ATLD, ataxia-teleangiectasia like disorder; AOA1, ataxia with oculomotor Apraxia type 1; AOA2, Ataxia with Oculomotor Apraxia type 2; CTX, Cerebrotendinous Xanthomatosis; NPC, Nieman-Pick disease type C; AVED, ataxia with Vitamin E deficiency; COQ10D4, Coenzyme Q10 deficiency-4.</p></caption>
<graphic xlink:href="fnint-17-1275794-g002.tif"/>
</fig>
<p>Another important source to investigate the neurodegeneration in ARCAs comes from the parametrization of the optic nerve and macular areas by the Optical Coherence Tomography (OCT; <xref ref-type="bibr" rid="ref15">Biousse et al., 2020</xref>). The assessment of the retinal thickness at the macular and optic nerve levels, measuring, respectively, the density of ganglion cells (GC) and retinal nerve fiber layers (RNFL), is often included in protocols for the phenotypic characterization of ARCAs and, in particular, for follow-up studies of Friederich&#x2019;s ataxia (FRDA), Spastic Paraplegia 7 (SPG7) and Spastic Ataxia of Cherlevoix-Saguenay type (ARSACS).</p>
<p>In mitochondrial optic neuropathies OCT has proven to be a valuable tool with high diagnostic and prognostic value, also predicting the involvement of the fellow eye (<xref ref-type="bibr" rid="ref3">Asanad et al., 2019</xref>). Notably, mitochondrial pathogenesis characterizes a significant subgroup of ARCAs, and such as FRDA, POLG-related ataxia, ARSACS, and SPG7, in which mutations of nuclear genes directly affect mitochondrial proteins, but also other forms, such as Ataxia-Teleangiectasia (AT), Ataxia-Teleangiectasia Like disease (ATLD), Ataxia with Ocular Apraxia 1 and 2 (AOA1, AOA2), Spinocerebellar ataxia with axonal neuropathy1 (SCAN 1), in which mitochondrial functions are also indirectly compromised.</p>
<p>In this paper we suggest the use of some robust eye findings as possible markers in the parametrization of ARCAs. We firstly resume the clinical ocular findings in different types of ARCAs thus providing a possible diagnostic classification approach according to ocular features deriving from the study of eye movements. Secondly, we discuss the quantification of the GC and RNFL thickness as a marker of neurodegeneration in hereditary ataxias. Lastly, we discuss how the advancement of computer science is making available and easier the study, diagnosis and analysis of ocular parameters.</p>
</sec>
<sec id="sec2">
<title>Diagnostic approach and common pathways underlying ARCAs</title>
<p>ARCAs are actually classified according to the most frequent ataxia-associated syndrome and to the underlying mutated gene (<xref ref-type="bibr" rid="ref8">Beaudin et al., 2019</xref>; <xref ref-type="table" rid="tab1">Table 1</xref>). However, the great phenotypic overlapping existing among ataxias sub-types categorized in different classes, increases the risk of missing the correct diagnosis and the appropriate treatments, even for the actually druggable types (i.e., Cerebrotendinous Xanthomatosis&#x2014;CTX; Nieman-Pick&#x2014;NPC; Ataxia with Vitamin E deficiency&#x2014;AVED). To date, more than 90 autosomal-recessive disorders having ataxia as a predominant feature, as many, having ataxia as less predominant component (<xref ref-type="bibr" rid="ref110">Rossi et al., 2018</xref>). This genetic pleiotropy is further augmented by the growing number of genes associated with both autosomal dominant ataxias and severe early-onset autosomal recessive ataxia syndromes (e.g., AFG3L2/SCA 28, SPTBN2/SCA5, ITPR1/SCA29, OPA1; <xref ref-type="bibr" rid="ref110">Rossi et al., 2018</xref>). The advent of Next-Generation Sequencing (NGS) techniques has raised the diagnostic capacities and, at the same time, it has amplified the diagnostic complexity with ever-expanding pleiotropy of ARCAs genes (<xref ref-type="bibr" rid="ref53">Galatolo et al., 2021</xref>). However, the wide used NGS approaches have the limitation of being unavailable in detecting pathological noncoding triplet expansions, such those occurring in FRDA or CANVAS, which are common ARCAs types. Furthermore, the diagnostic rate of NGS may reduce in case of mutations in new disease genes, deep intronic mutations, mutations in regulatory regions, gene dosage effects, or digenic modes of inheritance and epigenetic changes (<xref ref-type="bibr" rid="ref17">Bonifert et al., 2014</xref>; <xref ref-type="bibr" rid="ref87">Minnerop et al., 2017</xref>). Moreover, some genes may cause ataxia and spastic paraplegia suggesting a genetic and phenotypic continuum between Cerebellar ataxias (CA) and Hereditary Spastic paraplegias (<xref ref-type="bibr" rid="ref128">Synofzik and Sch&#x00FC;le, 2017</xref>). A stepwise diagnostic workout is currently recommended in ARCAs, starting from accurate clinical characterization, then testing a single gene when the suspicion is highly supported by the family history and presence of specific markers; alternatively it is suggested to test FRDA first, and then a NGS panel of genes or a whole exome sequencing.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption><p>ARCAs classification by pathways involvement.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Pathways</th>
<th align="left" valign="top">Disease name (#OMIM)</th>
<th align="left" valign="top">Gene (protein)</th>
<th align="left" valign="top">Protein function</th>
<th align="left" valign="top">Inheritance (AD, autosomal dominant, AR, autosomal recessive)</th>
<th align="left" valign="top">Type of mutation</th>
<th align="left" valign="top">Gain of function/loss of function</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" colspan="7"><bold>Mitochondrial pathways</bold></td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Friedreich ataxia (#229300)</td>
<td align="left" valign="top"><italic>FXN</italic> (frataxin)</td>
<td align="left" valign="top">Inner mitochondrial membrane protein regulating iron&#x2013;sulfur cluster biogenesis</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">96%: biallelic GAA repeat expansion within intron 1 (affected individuals have from 70 to more than 1,000 GAA triplets); 4%: monoallelic abnormally expanded GAA repeat and another intragenic pathogenic variant in the other allele</td>
<td align="left" valign="top">96% loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Mitochondrial recessive ataxia syndrome including SANDO and SCAE (#607459)</td>
<td align="left" valign="top"><italic>POLG</italic> (DNA polymerase subunit gamma-1)</td>
<td align="left" valign="top">The only DNA polymerase in humans that replicates and repairs mtDNA</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">&#x003E;95%: SNV or small intragenic deletions/insertions pathogenic variants; Very rare: deletion/duplication.</td>
<td align="left" valign="top">Loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Q10 deficiency-4 (#612016)</td>
<td align="left" valign="top"><italic>COQ8A</italic> or <italic>ADCK3</italic> (Coenzyme Q8A)</td>
<td align="left" valign="top">Coenzyme Q10 synthesis (Coenzyme Q10 is essential for proper functioning of the mitochondrial respiratory chain)</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">SNV or small intragenic deletions/insertions pathogenic variants</td>
<td align="left" valign="top">&#x201C;Ataxia-simplex phenotype,&#x201D; more frequent with biallelic LOF variants; multisystemic phenotypes more frequently associated with missense variants (possible gain-of-function or dominant-negative effect)</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Spastic paraplegia 7 (# 607259)</td>
<td align="left" valign="top"><italic>SPG7</italic> (paraplegin)</td>
<td align="left" valign="top">Paraplegin-AFG3L2 complex is involved in mitochondrial protein maturation and degradation; its inactivation causes reduced mitochondrial complex I activity</td>
<td align="left" valign="top">AD, AR</td>
<td align="left" valign="top">&#x003E;98%: SNV or small intragenic deletions/insertions pathogenic variants; &#x003C;2%: deletion/duplication</td>
<td align="left" valign="top">Loss of function variants and missense variants</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Spastic ataxia 5, SPAX5 (# 614487)</td>
<td align="left" valign="top"><italic>AFG3L2</italic> (catalytic subunit of the m-AAA protease)</td>
<td align="left" valign="top">Paraplegin-AFG3L2 complex is involved in mitochondrial protein maturation and degradation. The m-AAA protease, an ATP-dependent proteolytic complex of the mitochondrial inner membrane that degrades misfolded proteins and regulates ribosome assembly</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">Biallelic SNV or small intragenic deletions/insertions pathogenic variants</td>
<td align="left" valign="top">Loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Spinocerebellar Ataxia 28, SCA28 (# 610246)</td>
<td align="left" valign="top"><italic>AFG3L2</italic></td>
<td align="left" valign="top">See above</td>
<td align="left" valign="top">AD</td>
<td align="left" valign="top">&#x003E;99%: SNV or small intragenic deletions/insertions pathogenic variants; Extremely rare: monoallelic deletion/duplication</td>
<td align="left" valign="top">Loss of function variants and gain of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Spastic ataxia of the Charlevoix-Saguenay type, SACS, or ARSACS (# 270550)</td>
<td align="left" valign="top"><italic>SACS</italic> (sacsin)</td>
<td align="left" valign="top">Chaperon activities, controlling the microtubule balance or cell migration. Regulating the mitochondrial functions</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">~95%: SNV or small intragenic deletions/insertions pathogenic variants; ~5%: deletion/duplication</td>
<td align="left" valign="top">Loss of function variants</td>
</tr>
<tr>
<td align="left" valign="top" colspan="7"><bold>DNA repair/genome stability</bold></td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Ataxia-telangiectasia, AT (# 208900)</td>
<td align="left" valign="top"><italic>ATM</italic> (ATM)</td>
<td align="left" valign="top">Serine/threonine protein kinase of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family. In response to double strand breaks, ATM restores damaged sites, by phosphorylating numerous substrates.</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">~90%: SNV or small intragenic deletions/insertions pathogenic variants; 1%&#x2013;2%: deletion/duplication</td>
<td align="left" valign="top">Loss of function (prevalent) and gain of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Ataxia-telangiectasia like disorder, ATLD (# 604391)</td>
<td align="left" valign="top"><italic>MRE11A</italic> (MRE11A)</td>
<td align="left" valign="top">DNA repair (Mre11-Rad50-Nbs1 complex recruits ATM to the site of double strand breaks in nuclear DNA)</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">n.a.</td>
<td align="left" valign="top">Loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Ataxia-oculomotor apraxia type 1, AOA1 (# 208920)</td>
<td align="left" valign="top"><italic>APTX</italic> (aprataxin)</td>
<td align="left" valign="top">Nuclear protein with hydrolase activities interacting with different pathways implicated in single-strand and double-strand repair mechanisms</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">n.a.</td>
<td align="left" valign="top">Loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Ataxia with oculomotor apraxia type 2 (AOA2, SETX gene)</td>
<td align="left" valign="top"><italic>SETX</italic> (senataxin)</td>
<td align="left" valign="top">Ubiquitous high conservate RNA/DNA helicase that has been implicated in transcriptional regulation and the DNA damage response through resolution of R-loop structures</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">~80%&#x2013;92%: SNV or small intragenic deletions/insertions pathogenic variants; ~8%&#x2013;20%: deletion/duplication</td>
<td align="left" valign="top">Loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Amyotrophic lateral sclerosis 4, ALS4 (# 602433)</td>
<td align="left" valign="top"><italic>SETX</italic> (senataxin)</td>
<td align="left" valign="top">See above</td>
<td align="left" valign="top">AD</td>
<td align="left" valign="top">See above</td>
<td/>
</tr>
<tr>
<td/>
<td align="left" valign="top">Cerebellar Ataxia Neuropathy Vestibular Areflexia Syndrome, CANVAS (# 614575)</td>
<td align="left" valign="top"><italic>RFC1</italic> (subunit of replication factor C)</td>
<td align="left" valign="top">Large subunit of replication factor C (RFC), a heteropentameric AAA+ protein complex associated with DNA synthesis during replication and repair</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">biallelic pentanucleotide repeat expansion (AAGGG; 400 to 2,000 repeats). However, expansions may be AAAAG, AAAGG, AAGAG, AGAGG, ACAGG or AAGGG; imperfect repeats w/interruptions are also possible.</td>
<td align="left" valign="top">Unknown</td>
</tr>
<tr>
<td align="left" valign="top" colspan="7"><bold>Complex lipids metabolism</bold></td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Niemann-Pick-type C disease, NPC (# 257220)</td>
<td align="left" valign="top"><italic>NPC1</italic> (95%) and <italic>NPC2</italic> (5%; NPC Intracellular Cholesterol Transporter 1 and 2)</td>
<td align="left" valign="top">Cellular trafficking of cholesterol and other lipids</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top"><italic>NPC1</italic>: 76% SNV or small intragenic deletions/insertions pathogenic variants; 22% deletion/duplication; 2% large deletions/duplications; <italic>NPC2</italic>: 88% SNV or small intragenic deletions/insertions pathogenic variants; 12% deletion/duplication</td>
<td align="left" valign="top">Loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Cerebrotendinous Xanthomatosis, CTX (#213700)</td>
<td align="left" valign="top"><italic>CYP27A1</italic> (mitochondrial sterol 27-hydroxylase)</td>
<td align="left" valign="top">Mitochondrial sterol 27-hydroxylase</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">99%: SNV or small intragenic deletions/insertions pathogenic variants; 1%: deletion/duplication</td>
<td align="left" valign="top">Loss of function</td>
</tr>
<tr>
<td/>
<td align="left" valign="top">Ataxia with vitamin E deficiency, AVED (# 277460)</td>
<td align="left" valign="top"><italic>TTPA</italic> (Alpha Tocopherol Transfer Protein)</td>
<td align="left" valign="top">Protein that binds alpha-tocopherol, a form of vitamin E, and regulates vitamin E levels by transporting vitamin E between membrane vesicles and facilitating the secretion of vitamin E from hepatocytes to circulating lipoproteins.</td>
<td align="left" valign="top">AR</td>
<td align="left" valign="top">&#x003E;90%: SNV or small intragenic deletions/insertions pathogenic variants</td>
<td align="left" valign="top">Loss of function</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>New mathematical methods have recently emerged for dealing with complexity of neurodegenerative disorders such as ARCAs; these methods are grounded on the application of the complex system frameworks, to assess interactions between intricate pathologic pathways underlying various <italic>CA</italic>. This approach allows us to identify a restrict number of pathologic nodes to which converge different metabolic pathways, that might even be shared across several ARCAs. This allows connecting genetically different diseases and focusing on molecular pathways shared across them, but also across other neurodegenerative diseases that may be targeted by common treatments and eventually monitored by the same biomarkers (<xref ref-type="bibr" rid="ref127">Synofzik et al., 2019</xref>). However, despite the presence of such common pathways, the consequent pathogenetic cascade mechanisms may induce minor or greater impact on central nervous system structures, likely leading to variable ocular findings. In the cerebellum, this variability might be explained also by the presence of regions characterized by a different cells&#x2019; susceptibility due to a different glia-to-neuron ratio and consequent different energy demand (<xref ref-type="bibr" rid="ref41">Emir et al., 2021</xref>). Three main pathological nodes to which converge different phenotypes can be identified in ARCAs (<xref ref-type="table" rid="tab1">Table 1</xref>):</p>
<list list-type="order">
<list-item><p>Mitochondrial metabolism</p></list-item>
<list-item><p>DNA repair/genome stability</p></list-item>
<list-item><p>Complex lipids metabolism</p></list-item>
</list>
<p>According to such three common pathways underlying ARCAs, we underly the presence of some robust eye findings that reinforce this new possible classification and can be used as possible markers in the parametrization of ARCAs.</p>
</sec>
<sec id="sec3">
<title>Oculomotor phenotypic characterization of ARCAs</title>
<sec id="sec4">
<title>Mitochondrial pathways (FRDA, POLG, COQ8A, SPG7, SPAX5, and ARSACS)</title>
<p>Mitochondrial-induced high susceptibility to oxidative stress and free radicals&#x2019; toxicity and apoptosis mainly characterizes Friedreich ataxia (FRDA), POLG-related disorders and Coenzyme Q10 deficiency-4 (COQ10D4).</p>
<p>Among these, the most common genetically determined cerebellar ataxia is FRDA, a mixed ataxia with greater involvement of the posterior horns of the spinal cord and the dorsal root ganglia associated with progressive neurodegeneration of the cerebellum, cortico-spinal tracts, afferent visual pathway and systemic involvement (<xref ref-type="table" rid="tab2">Table 2</xref>). FRDA is due to GAA repeat expansion within intron 1 of <italic>FXN</italic> gene resulting in decreased levels of Frataxin, which is an inner mitochondrial membrane protein regulating iron&#x2013;sulfur (Fe-S) cluster biogenesis (<xref ref-type="bibr" rid="ref36">Delatycki and Bidichandani, 2019</xref>). Thus, the primary event following frataxin deficiency seems to be the loss of Fe-S cluster biogenesis. Fe-S clusters are implicated in different cellular functions ranging from mitochondrial respiration, iron metabolism and translation to DNA repair. Frataxin inactivation is thus associated with increased cellular susceptibility to oxidative stress-toxicity (<xref ref-type="bibr" rid="ref80">Martelli and Puccio, 2014</xref>) involving the nervous system and the visual pathway. Although in FRDA the papillomacular axonal system is not preferentially involved, in line with a progressive scattered loss of RGCs, complexes I, II and III are all involved, thus limiting possible compensatory mechanisms (<xref ref-type="bibr" rid="ref48">Fortuna et al., 2009</xref>). FRDA patients usually show loss of large principal neurons and synaptic terminals in the dentate nucleus and possibly Purkinje cell injury (<xref ref-type="bibr" rid="ref68">Kemp et al., 2016</xref>). This cascade mechanism may underlies also the various oculomotor abnormalities observed in FRDA: these include fixation instability with high rate of square wave jerks (SWJs), ocular flutter and gaze-evoked nystagmus, impaired smooth pursuit, increased latency of saccades and saccadic dysmetria (<xref ref-type="bibr" rid="ref51">Furman et al., 1983</xref>; <xref ref-type="bibr" rid="ref63">Hocking et al., 2010</xref>). Vestibulo-ocular reflexes and visual&#x2013;vestibular interactions are also compromised (<xref ref-type="bibr" rid="ref43">Fahey et al., 2008</xref>; <xref ref-type="bibr" rid="ref82">Maudoux et al., 2020</xref>). Significant correlations have been reported between saccadic latency and disease severity as measured by the Friedreich Ataxia Rating Scale (FARS) and between fixation instability and age of disease onset. High order visual spatial abnormalities and deficits in disengaging fixation and executive functions have been reported in FRDA using gap-overlap, antisaccadic and memory guided paradigms (<xref ref-type="bibr" rid="ref106">Rojas et al., 2021</xref>). Interestingly, the presentation and progression of compound heterozygotes FRDA patients may depend on the type of mutation on the second allele: loss-of-function mutations are associated with a significantly earlier age of onset; missense mutations on the second allele are often associated to optic neuropathy (<xref ref-type="bibr" rid="ref93">Newman et al., 2023</xref>).</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption><p>Main oculomotor and fundoscopic findings.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top" colspan="11">Impaired eye movements</th>
<th align="center" valign="top" colspan="5">Ophthalmoscopic and other ocular changes</th>
</tr>
<tr>
<th/>
<th align="center" valign="top">Ptosis (drooping of the upper eyelid)</th>
<th align="center" valign="top">Nystagmus (rhythmic, involuntary, rapid, back and forth movement of the eyes)</th>
<th align="center" valign="top">Oscillopsia (illusion of an unstable visual world)</th>
<th align="center" valign="top">Vertical gaze impairment/palsy</th>
<th align="center" valign="top">Dysmetria</th>
<th align="center" valign="top">Increased latency/ocular apraxia (horizontal gaze failure due to deficits in starting voluntary/reactive eye movements)</th>
<th align="center" valign="top">Saccadic intrusions (conjugate small involuntary saccadic movements that disrupt visual fixation)</th>
<th align="center" valign="top">Impaired smooth pursuit (disturbance in maintain the line of sight on smoothly moving targets)</th>
<th align="center" valign="top">Impaired vestibulo ocular reflex (VOR is a reflex that maintains stable vision during rapid head rotations)</th>
<th align="center" valign="top">Extraocular muscles ophthalmoplegy</th>
<th align="center" valign="top">Strabismus (misaligned eyes)</th>
<th align="center" valign="top">Optic Atrophy</th>
<th align="center" valign="top">Optic nerve pallor</th>
<th align="center" valign="top">Juvenile cataract</th>
<th align="center" valign="top">Drusen (subretinal pigment epithelial deposit)</th>
<th align="center" valign="top">Retinitis pigmentosa</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" colspan="17"><bold>Mitochondrial pathways</bold></td>
</tr>
<tr>
<td align="left" valign="top">POLG</td>
<td align="center" valign="top">x</td>
<td align="center" valign="top">X</td>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">SPG7</td>
<td align="center" valign="top">x</td>
<td align="center" valign="top">X</td>
<td/>
<td align="center" valign="top">X</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">ARSACS</td>
<td/>
<td align="center" valign="top">X</td>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">FRDA</td>
<td/>
<td align="center" valign="top">X</td>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="17"><bold>DNA repair/genome stability</bold></td>
</tr>
<tr>
<td align="left" valign="top">AT</td>
<td/>
<td align="center" valign="top">X</td>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">AOA1</td>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td align="center" valign="top">X</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">AOA2</td>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td align="center" valign="top">X</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">ATLD</td>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td align="center" valign="top">x</td>
<td align="center" valign="top">x</td>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top">CANVAS</td>
<td/>
<td align="center" valign="top">x</td>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td align="left" valign="top" colspan="17"><bold>Complex lipid metabolism</bold></td>
</tr>
<tr>
<td align="left" valign="top">NPC</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">X</td>
<td align="center" valign="top">x</td>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td align="center" valign="top">x</td>
<td/>
<td align="center" valign="top">x</td>
<td align="center" valign="top">x</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">AVED</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
<td/>
<td/>
<td/>
<td/>
<td align="center" valign="top">x</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Mutations in the mitochondrial DNA <italic>polymerase subunit gamma &#x201C;POLG&#x201D;</italic>, responsible for the replication and repair of mitochondrial DNA, are increasing recognized causes of ataxia and peripheral neuropathy, variably associated to cerebellar or extracerebellar oculomotor changes (<xref ref-type="bibr" rid="ref148">Wong et al., 2008</xref>). <italic>POLG</italic> mutations result in mitochondrial DNA depletion and/or multiple deletions (<xref ref-type="bibr" rid="ref102">Rahman and Copeland, 2019</xref>) and are responsible of different phenotypes including <italic>POLG related ataxia-neuropathy disorders (SANDO/MIRAS/arPEO plus)</italic>.</p>
<p><italic>POLG</italic> mutations are associated to premature mitochondrial dysfunction with increased oxidative stress and nuclear DNA damage, apoptosis activation, repression of regulators of mitochondrial biogenesis and cellular antioxidant response (<xref ref-type="bibr" rid="ref28">Compton et al., 2011</xref>; <xref ref-type="bibr" rid="ref91">Naess et al., 2011</xref>; <xref ref-type="bibr" rid="ref111">Rouzier et al., 2014</xref>; <xref ref-type="bibr" rid="ref112">Safdar et al., 2016</xref>). Secondary to these primary dysfunctions and similarly to what observed in FRDA, multiple pathways with differential cell vulnerability are involved (<xref ref-type="bibr" rid="ref130">Synofzik et al., 2012</xref>). In <italic>POLG</italic>-mutated patients a severe myelin loss of the dentate and other deep cerebellar nuclei outflow tract was observed (<xref ref-type="bibr" rid="ref74">Lax et al., 2012</xref>). In line with the expected muscular weakness associated to mitochondrial dysfunction, ophthalmoparesis and ptosis are the most frequently reported oculomotor finding in different POLG phenotypes (<xref ref-type="bibr" rid="ref102">Rahman and Copeland, 2019</xref>). GEN and saccade dysmetria are also observed (unpublished data). Interestingly, hypertrophy of inferior olives has been described in several cases, and palatal tremor was reported in one case (<xref ref-type="bibr" rid="ref137">Tilikete and Virginie, 2017</xref>), but no eye movements recording are available. Optic atrophy and pigmentary changes have been described in some cases (<xref ref-type="bibr" rid="ref102">Rahman and Copeland, 2019</xref>).</p>
<p>Cerebellar ataxia with exercise intolerance characterizes biallelic <italic>COQ8A</italic> mutations leading to deficit in the CoQ10 biogenesis (<xref ref-type="bibr" rid="ref116">Salviati et al., 2012</xref>; <xref ref-type="bibr" rid="ref19">Caglayan et al., 2019</xref>). Fibroblast cell lines derived from mutated patients showed signs of oxidative stress and dysfunction in mitochondrial homeostasis (<xref ref-type="bibr" rid="ref32">Cullen et al., 2016</xref>). <xref ref-type="bibr" rid="ref139">Trasch&#x00FC;tz et al. (2020)</xref> studied genotype/phenotype correlations in patients with biallelic loss-of-function (LOF) and missense <italic>COQ8A</italic> mutations: they found that an &#x201C;ataxia-simplex phenotype&#x201D; was more frequent in patients with biallelic LOF variants, and conversely, missense variants having a possible dominant-negative effect were more often associated with multisystemic involvement beyond ataxia. The main phenotypic features of a large cohort of patients harboring biallelic <italic>COQ8A</italic> variants included early onset progressive cerebellar ataxia, seizures, cognitive impairment, hyperkinetic movement disorders and MR imaging of prevalent cerebellar vermal (100%) and hemisphere atrophy with dentate and pontine nuclei T2 hyperintensities (<xref ref-type="bibr" rid="ref64">Horvath et al., 2012</xref>). Reported oculomotor abnormalities are ocular apraxia, slow saccades, and gaze palsy. Inconstant retinal pigmentary changes, cataracts, optic atrophy and hearing loss have also been reported (<xref ref-type="bibr" rid="ref139">Trasch&#x00FC;tz et al., 2020</xref>). Unfortunately, eye movements are neither described nor recorded in this cohort even if according to neuroimaging of cerebellum and brainstem, the involvement of ocular motor system is likely.</p>
<p>Mitochondrial-related impairment of axonal transport mainly underlies spastic ataxias, particularly SPG7, in which ataxia and spasticity are often associated to impairment of optic pathway. Signs of cerebellar and extracerebellar oculomotor involvement and PEO are also described in these forms (<xref ref-type="bibr" rid="ref35">de Bot et al., 2012</xref>; <xref ref-type="bibr" rid="ref142">van Gassen et al., 2012</xref>; <xref ref-type="bibr" rid="ref100">Pfeffer et al., 2014</xref>; <xref ref-type="bibr" rid="ref128">Synofzik and Sch&#x00FC;le, 2017</xref>). <italic>SPG7</italic> mutations affect the function of <italic>Paraplegin</italic>, an inner mitochondrial protein which assembles with homologous AFG3L2, to form the oligomeric mAAA protease complex (<xref ref-type="bibr" rid="ref22">Casari et al., 1998</xref>; <xref ref-type="bibr" rid="ref58">Giorgio and Roberto, 2018</xref>). The paraplegin-AFG3L2 complex is involved in mitochondrial protein maturation and degradation and its inactivation causes reduced mitochondrial complex I activity (<xref ref-type="bibr" rid="ref42">Estrada-Cuzcano et al., 2017</xref>). Loss of AFG3L2 function is associated with autosomal recessive spastic ataxia 5 (SPAX5) and autosomal dominant spinocerebellar ataxia 28 (SCA28) with myopathy and CPEO (<xref ref-type="bibr" rid="ref37">di Bella et al., 2010</xref>; <xref ref-type="bibr" rid="ref140">Tulli et al., 2019</xref>).</p>
<p>Although SPG7 has been classically considered to show an autosomal recessive mode of inheritance, there is also evidence for autosomal dominant transmission in some families (<xref ref-type="bibr" rid="ref117">S&#x00E1;nchez-Ferrero et al., 2013</xref>). The predominance of pyramidal signs is significantly associated to biallelic LOF variants rather than missense variants, suggesting that the loss of paraplegin function drives spasticity. Probably LOF of paraplegin still allows AFG3L2 to form functional oligomeric m-AAA protease and this could compensate for loss of paraplegin in the cerebellum because of the high AFG3L2 cerebellar expression (<xref ref-type="bibr" rid="ref26">Coarelli et al., 2019</xref>). Moreover, nonsense variants on both alleles are associated to a more severe phenotype including ophthalmologic involvement. Multiple mitochondrial and extra-mitochondrial changes results from any dysfunctional <italic>paraplegin</italic>, including defective axonal transport particularly in synaptic terminals of long tract axons such as cortico-spinal and optic tracts with subsequent retrograde degeneration (<xref ref-type="bibr" rid="ref24">Charif et al., 2020</xref>). Peripheral nerves are spared in SPG7, and this may differentiate SPG7 patients from ARSACS patients showing prominent peripheral sensory motor neuropathy and distal amyotrophy. SPG7 patients showed increased T2 signal from the dentate nucleus (<xref ref-type="bibr" rid="ref62">Hewamadduma et al., 2018</xref>), in line with the postmortem data demonstrating neuronal loss in the dentate nucleus (<xref ref-type="bibr" rid="ref134">Thal et al., 2015</xref>). The most frequently described oculomotor defect in SPG7 patients is the adult onset progressive external ophthalmoplegia and ptosis (CPEO; <xref ref-type="bibr" rid="ref71">Klebe et al., 2012</xref>; <xref ref-type="bibr" rid="ref142">van Gassen et al., 2012</xref>). However, cerebellar nystagmus and vertical gaze limitation with slow upward saccades and preserved VOR have also been reported. Supranuclear gaze palsy, seldom reported in SPG7, may be due to extension of neurodegeneration to the brainstem nuclei and pathways as demonstrated by pathologic studies (<xref ref-type="bibr" rid="ref134">Thal et al., 2015</xref>).</p>
<p><italic>Sacsin</italic> is involved in chaperon activities, controlling the microtubule balance or cell migration and it plays a crucial role in regulating the mitochondrial functions (<xref ref-type="bibr" rid="ref88">Morani et al., 2019</xref>). Loss of function of <italic>Sacsin</italic> causes <italic>autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)</italic>, the second most common ARCAs (<xref ref-type="bibr" rid="ref129">Synofzik et al., 2013</xref>; <xref ref-type="bibr" rid="ref18">Bradshaw et al., 2016</xref>; <xref ref-type="bibr" rid="ref143">Vermeer et al., 2020</xref>). Sacsin deficiency determines an altered organization of intermediate filaments and consequently multiple mitochondrial dysfunctions involving mitochondrial fission (<xref ref-type="bibr" rid="ref59">Girard et al., 2012</xref>), oxidative phosphorylation, and oxidative stress pathways (<xref ref-type="bibr" rid="ref30">Criscuolo et al., 2015</xref>). This cascade of events may explain the presence of different clinical features partially reminiscent of mitochondrial disorders. Spastic ataxia is associated to peripheral mixed sensory motor neuropathy, progressive distal amyotrophy, mild intellectual disability, psychiatric symptoms, thickened optic disks and retinal architecture changes (<xref ref-type="bibr" rid="ref5">Baets et al., 2010</xref>). Vermal and hemispheric cerebellar atrophy is a characteristic MRI finding, seldom associated to pontine hyperintensities, explaining the cerebellar origin of oculomotor and gaze holding changes. Cerebellar oculomotor deficits are clinically evident also in the atypical (only peripheral neuropathy) phenotypes of ARSACS (<xref ref-type="bibr" rid="ref145">Vill et al., 2018</xref>) and include GEN and rebound nystagmus, saccadic pursuit and saccadic abnormalities. A supranuclear gaze palsy has also been reported in one patient (<xref ref-type="bibr" rid="ref124">Stevens et al., 2013</xref>) while VOR changes have been not investigated.</p>
</sec>
<sec id="sec5">
<title>DNA repair/genome stability (AT, ATLD, AOA2, AOA1, AOA4, SCAN1, and RFC1-CANVAS)</title>
<p>Autosomal recessive ataxia with oculomotor apraxia (OMA), elevated levels of serum alpha-fetoprotein (AFP biomarker) and distinct mutations of genes implicated in DNA repair and/or transcription, define a group of early onset disorders including: ataxia-telangiectasia (<italic>ATM</italic> gene), ataxia-telangiectasia like disorder (<italic>MERR11</italic> gene) ataxia with oculomotor apraxia type 1 (AOA1, <italic>APTX</italic> gene) and type 2 (AOA2, <italic>SETX</italic> gene; <xref ref-type="bibr" rid="ref20">Caldecott, 2003</xref>). These disorders, share common oculomotor abnormalities which demonstrate the functional failure of the cerebellar brainstem networks and vestibular system, and impairment of supranuclear input for the voluntary control of eye movement. Both oculomotor apraxia and long latency multistep saccades with oculocephalic dissociation are present in all disorders.</p>
<p><italic>Ataxia-Telangiectasia (AT)</italic> and <italic>Ataxia-Telangiectasia Like Disorder (ATLD)</italic> are clinically similar conditions, with ATLD being very rare, less severe, and slowly progressive. AT is an early onset ARCAs due to mutations in <italic>ATM</italic>, encoding a serine/threonine protein kinase of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family (<xref ref-type="bibr" rid="ref56">Gatti et al., 1999</xref>). In response to double strand breaks, ATM restores damaged sites (<xref ref-type="bibr" rid="ref46">Fernandez-Capetillo et al., 2004</xref>). Also, <italic>MRE11</italic>, gene associated to ATLD, contributes to DNA repair, since this gene is part of the <italic>Mre11-Rad50-Nbs1</italic> complex (MRNcomplex). Both MRE11 and ATM respond to several stress and regulates multiple cellular pathways, explaining the multisystemic features observed in AT including degeneration of diverse neuronal systems (cerebellar, cortical, peripheral), increased sensitivity to ionizing radiation, cancer, immune deficiency, and diabetes (<xref ref-type="bibr" rid="ref12">Bian et al., 2019</xref>). Conjunctival, auricular and buccal telangiectasias may be included in the AT phenotype. A recurrent MRI finding is the cerebellar atrophy mostly involving the vermis, in line with patients&#x2019; oculomotor presentation, and the anterior lobe, consistent with limb ataxia (<xref ref-type="bibr" rid="ref50">Frismand et al., 2013</xref>). Cerebellar syndrome is progressively associated to other hyperkinetic disorders such as dystonia, chorea and peripheral sensory-motor axonal neuropathy (<xref ref-type="bibr" rid="ref125">Stewart et al., 1999</xref>). Oculomotor abnormalities in AT and ATLD patients are mostly characterized by deficit in saccadic initiation and metrics, fixation, gaze holding, pursuits and VOR with oculocephalic incoordination (<xref ref-type="bibr" rid="ref95">Palmeri et al., 2013</xref>; <xref ref-type="bibr" rid="ref45">Federighi et al., 2017</xref>). Patients may show long latency reflexive saccades and even longer or absent volitional saccades, requiring a head thrust and blinking to, respectively, force eye deviation and reset eye position to allow the eyes to finally move into the desired position (<xref ref-type="bibr" rid="ref150">Zee et al., 1977</xref>; <xref ref-type="bibr" rid="ref6">Baloh, 1978</xref>). Saccades are hypometric or interrupted, with a characteristic stepwise gaze shift (<xref ref-type="bibr" rid="ref132">Tang and Shaikh, 2019</xref>). Fixation is affected by spontaneous nystagmus (horizontal and vertical), slow drifts, periodic alternating nystagmus, and saccadic intrusions ranging from SWJ saccadic intrusions to micro-or macro saccadic oscillations and flutter (<xref ref-type="bibr" rid="ref77">Lewis et al., 1999</xref>; <xref ref-type="bibr" rid="ref122">Shaikh et al., 2009</xref>, <xref ref-type="bibr" rid="ref121">2011</xref>).</p>
<p><italic>AOA1 and AOA2</italic> share similar oculomotor findings and clinical/MRI features, with AOA1 patients having early-onset slowly progressive cerebellar ataxia associated to axonal neuropathy, chorea, dystonia (which gradually attenuate), optional hypoalbuminemia, hypercholesterolemia and normal to slight increase of alpha-fetoprotein (<xref ref-type="bibr" rid="ref2">Anheim et al., 2009</xref>). The loss of the normal hypointensity in the dentate nucleus was suggested as a highly sensitive and specific biomarker (<xref ref-type="bibr" rid="ref108">Ronsin et al., 2019</xref>). In AOA1, <italic>APTX</italic> mutations lead to dysfunctional <italic>aprataxin</italic> which is a nuclear protein implicated in single-strand and double-strand repair mechanisms (<xref ref-type="bibr" rid="ref34">Date et al., 2001</xref>; <xref ref-type="bibr" rid="ref75">Le Ber et al., 2003</xref>). Cerebellar ataxia and axonal neuropathy develop later (second decade of life) in AOA2 patients, as well as pyramidal signs, dystonia, and chorea. AOA2 is due to dysfunctional <italic>Senataxin</italic> which is a ubiquitous high conservate RNA/DNA helicase implicated in transcriptional regulation and DNA damage response through resolution of R-loop structures (<xref ref-type="bibr" rid="ref105">Richard and Rosonina, 2021</xref>). Mutations in <italic>SETX</italic> result in either of two distinct neurodegenerative disorders: recessive mutations are responsible for AOA2 (<xref ref-type="bibr" rid="ref89">Moreira et al., 2004</xref>), while dominant mutations result in a juvenile form of amyotrophic lateral sclerosis (ALS) called ALS4 (<xref ref-type="bibr" rid="ref10">Bennett and La Spada, 2021</xref>). A study of 90 individuals with <italic>AOA2</italic> found that pathogenic missense variants in the helicase domain caused less severe AOA2 phenotypes than missense variants outside of this domain, or deletions, or truncating variants. However, individuals with pathogenic truncating or missense variants outside of the helicase domain had a lower frequency of pyramidal signs&#x2014;a finding that may reflect masking of pyramidal signs by severe motor neuropathy (<xref ref-type="bibr" rid="ref2">Anheim et al., 2009</xref>).</p>
<p>Cerebellar-based oculomotor changes are common to both AOAs, including OMA (long latency hypometric saccades) and excessive blinking, which is reported in around 50% of patients; fixation instability with SWJ, GEN, downbeat and rebound Ny, saccadic pursuit, hypermetric saccades and staircase saccades are also present. Reduced vertical and horizontal saccade velocity, supranuclear ophthalmoplegia, bilateral esotropia or monocular strabismus as well as marked deficits of voluntary saccades are more prominent in AOA2, where the age at onset and presence of occasional oculomotor apraxia were negatively correlated to disease progression; ophthalmoplegia (no strabismus) was positively correlated to the progression of neurological disability (<xref ref-type="bibr" rid="ref1">Anheim et al., 2010</xref>). Head trust with oculo-cephalic dissociation also develops in both conditions. In a recent study, hypometric saccades with a staircase pattern and no increased latency or head trust have been suggested to be a more reliable sign of oculomotor apraxia (<xref ref-type="bibr" rid="ref108">Ronsin et al., 2019</xref>; <xref ref-type="bibr" rid="ref7">Bargagli et al., 2021</xref>).</p>
<p><italic>Cerebellar Ataxia Neuropathy Vestibular Areflexia Sindrome (CANVAS)</italic> is a late onset familial or sporadic form of sensory ataxia caused by recessive biallelic pentanucleotide repeat expansion (AAGGG) in the <italic>RFC1 gene</italic> which encodes the large subunit of replication factor C (RFC), a heteropentameric AAA+ protein complex associated with DNA synthesis during replication and repair. The expansion sizes vary from 400 to 2,000 repeats in affected patients (<xref ref-type="bibr" rid="ref29">Cortese et al., 2019</xref>). The core CANVAS features are sensory neuronopathy, cerebellar ataxia, and a deficit of visually vestibulo-ocular reflex. Chronic spasmodic cough, oculomotor abnormalities usually including cerebellar ny and autonomic symptoms are also common (<xref ref-type="bibr" rid="ref131">Szmulewicz et al., 2016</xref>). MRI shows cerebellar atrophy involving the vermis and hemispheres with Crus 1 (<xref ref-type="bibr" rid="ref138">Trasch&#x00FC;tz et al., 2021</xref>). Oculomotor signs of vestibulocerebellar involvement are common in CANVAS, with progressive oscillopsia which can be permanent and mainly due to bilateral vestibular impairment. Nystagmus can be GEN, or downbeat, or combined; fixation instability both during head rotation, optokinetic ny, and during pursuit, and impaired vestibulo-ocular reflex and/or visuo-vestibular ocular reflex have been well described (<xref ref-type="bibr" rid="ref133">Terryn et al., 2020</xref>).</p>
<p>Sensory ataxia and severe peripheral sensory neuropathy is common to CANVAS, FRDA and POLG; however, ocular findings allow to distinguish these three entities. Vestibular areflexia, oscillopsia and Ny, although present in both CANVAS and FRDA, are more severe in the former, while in FRDA saccadic intrusions are more evident. Moreover, optic nerve pallor is typical of FRDA (<xref ref-type="bibr" rid="ref39">Dupr&#x00E9; et al., 2021</xref>). Ptosis, ophthalmoparesis, saccade dynamic and metric changes are typical of POLG.</p>
</sec>
<sec id="sec5a">
<title>Complex Lipids metabolism (NPC, CYP27A1 CTX, AVED)</title>
<p><italic>Complex Lipids metabolism disorders (NPC, CYP27A1 CTX, AVED)</italic> includes rare conditions in which cerebellar ataxia is associated to the involvement of other cerebral structures and extra-brain organs. Different extent of oculomotor system, retina and optic nerve involvement is common. <italic>Nieman-Pick-type C disease (NPC) i</italic>s a rare, autosomal recessive, neuro-visceral disorder caused by mutations in either the <italic>NPC1</italic> (95%) or <italic>NPC2</italic> (5%) genes (<xref ref-type="bibr" rid="ref92">Naureckiene et al., 2000</xref>; <xref ref-type="bibr" rid="ref98">Patterson, 2020</xref>), both involved in the cellular trafficking of cholesterol and other lipids. Mutations result in the accumulation in multiple tissues of non-esterified cholesterol, sphingolipids, sphingomyelin, and phospholipids that accumulate primarily in the central nervous system, causing the neurological manifestations (<xref ref-type="bibr" rid="ref65">Imrie et al., 2007</xref>). The metabolic pathway of the glycosphingolipids biosynthesis is the target of Miglustat, one of the approved treatments of NPC (<xref ref-type="bibr" rid="ref99">Patterson et al., 2017</xref>). NPC ranges from a neonatal, rapidly fatal disorder to an adult-onset variant, characterized by cerebellar ataxia, dystonia or other movement disorders that may occur with atypical schizophrenia or early-onset psychosis and early onset cognitive decline, including deficits in attention, language, and executive functions. A pattern of fronto-temporal dementia may also be present. Brain MRI shows cerebellar atrophy with involvement of cerebellar cortex and dentate nucleus (<xref ref-type="bibr" rid="ref146">Walterfang et al., 2012</xref>; <xref ref-type="bibr" rid="ref25">Chiba et al., 2014</xref>). Vertical supranuclear gaze palsy is the hallmark of the disorder, starting with a progressive slowing of vertical saccades which assume a typical curved trajectory. Vertical saccades are a marker of disease progression; they have been used in clinical trials and are recommended for testing the effect of Miglustat. <italic>Cerebrotendinous Xanthomatosis (CTX)</italic> is a rare inherited lipid storage disorder caused by deficiency of mitochondrial sterol 27-hydroxylase, related to mutations in the <italic>CYP27A1</italic> gene (<xref ref-type="bibr" rid="ref72">Koyama et al., 2021</xref>; <xref ref-type="bibr" rid="ref44">Federico and Gallus, 2022</xref>), ultimately leading to an increase of plasma and tissue cholestanol levels (<xref ref-type="bibr" rid="ref115">Salen and Steiner, 2017</xref>). The clinical symptomatology includes neonatal jaundice or cholestasis, diarrhea, tendon xanthomas, osteoporosis, coronary heart disease, juvenile cataracts, pulmonary involvement, progressive neuropsychiatric disturbances such as intellectual disability and dementia, psychiatric symptoms, pyramidal, extrapyramidal and cerebellar signs, and seizures (<xref ref-type="bibr" rid="ref84">Mignarri et al., 2014</xref>; <xref ref-type="bibr" rid="ref115">Salen and Steiner, 2017</xref>). Early replacement therapy with chenodeoxycholic acid may improve or even prevent CTX symptomatology (<xref ref-type="bibr" rid="ref123">Stelten et al., 2019</xref>).</p>
<p>At neuroimaging examination, the most distinctive findings are represented by MRI hyperintensities in FLAIR or T2-weighted images in the dentate nuclei and cerebellar white matter. Juvenile cataract is an early peculiar feature (<xref ref-type="bibr" rid="ref69">Khan et al., 2013</xref>; <xref ref-type="bibr" rid="ref136">Tibrewal et al., 2017</xref>; <xref ref-type="bibr" rid="ref49">Freedman et al., 2019</xref>). Electron microscopy of the cataract in a CTX patient disclosed membranous structures with vacuoles containing lipid materials. Replacement of cholesterol with cholestanol, leading to an impairment of lens function and alteration of cell membrane permeability, is considered the pathological substrate of cataracts in CTX (<xref ref-type="bibr" rid="ref83">McKenna et al., 1990</xref>; <xref ref-type="bibr" rid="ref38">Dotti et al., 2001</xref>). Optic disc atrophy and optic nerve abnormalities have been described in CTX patients (<xref ref-type="bibr" rid="ref141">Van Bogaert et al., 1937</xref>; <xref ref-type="bibr" rid="ref60">Guillain et al., 1942</xref>; <xref ref-type="bibr" rid="ref31">Cruysberg et al., 1995</xref>; <xref ref-type="bibr" rid="ref38">Dotti et al., 2001</xref>) and attributed to a defect in peripheral and central myelin synthesis related to the replacement of cholesterol with cholestanol. Other ophthalmic findings comprise retinal senescence, drusen, changes of retinal pigmented epitelium cells (<xref ref-type="bibr" rid="ref38">Dotti et al., 2001</xref>), xanthelasma (<xref ref-type="bibr" rid="ref31">Cruysberg et al., 1995</xref>), proptosis due to orbital xanthoma (<xref ref-type="bibr" rid="ref90">Morgan et al., 1989</xref>), increased content of sterol in the extraocular muscles (<xref ref-type="bibr" rid="ref114">Salen, 1971</xref>), bilateral exophthalmos (<xref ref-type="bibr" rid="ref73">Kuriyama et al., 1991</xref>), acquired type II red-green defect of Verriest (<xref ref-type="bibr" rid="ref31">Cruysberg et al., 1995</xref>). Efferent visual system abnormalities in CTX include gaze-evoked nystagmus and exotropia (<xref ref-type="bibr" rid="ref31">Cruysberg et al., 1995</xref>). Saccades are accurate with normal main sequence relationship, but CTX patients tend to execute more frequent multistep saccades and directional errors during the antisaccade task than controls. Increased saccadic latency, impaired precision, increased directional errors are characteristic of CTX patients with involvement of dentate nuclei at brain MRI (<xref ref-type="bibr" rid="ref109">Rosini et al., 2017</xref>).</p>
<p><italic>Ataxia with vitamin E deficiency (AVED)</italic> is a rare progressive multisystem disorder usually occurring in young childhood. It is caused by omozygous or compound heterozygous mutations in the &#x03B1;-tocopherol transfer protein gene (<italic>TTPA</italic>) (<xref ref-type="bibr" rid="ref119">Schuelke, 2023</xref>). Lack of gene product, a liver tocopherol-binding protein that incorporates alpha-tocopherol into nascent very-low-density lipoprotein (VLDL), causes vitamin E deficiency with subsequent systemic oxidative stress damage (<xref ref-type="bibr" rid="ref79">Mariotti et al., 2004</xref>). Peculiar AVED features include progressive ataxia, dystonia, axonal neuropathy, pyramidal signs, and impaired proprioception; less frequently, scoliosis, tendon xanthomas and xanthelasmata, seizures, psychotic episodes, intellectual decline, and cardiomyopathy have been reported (<xref ref-type="bibr" rid="ref52">Gabsi et al., 2001</xref>; <xref ref-type="bibr" rid="ref11">Benomar et al., 2002</xref>; <xref ref-type="bibr" rid="ref9">Becker et al., 2020</xref>). Neurological picture may resemble that of Friedreich&#x2019;s ataxia. Brain MRI findings vary from preserved cerebellar volumes to vermian or hemispheric cerebellar atrophy (<xref ref-type="bibr" rid="ref40">El Euch-Fayache et al., 2014</xref>). Purkinje cells deterioration is described in postmortem study (<xref ref-type="bibr" rid="ref79">Mariotti et al., 2004</xref>), as well as retinal atrophy with massive accumulation of lipofuscin (<xref ref-type="bibr" rid="ref118">Satya-Murti et al., 1986</xref>; <xref ref-type="bibr" rid="ref149">Yokota et al., 2000</xref>). Retinitis pigmentosa is the most frequent neuro-ophthalmological feature (<xref ref-type="bibr" rid="ref149">Yokota et al., 2000</xref>; <xref ref-type="bibr" rid="ref40">El Euch-Fayache et al., 2014</xref>); in one case-report, macular degeneration has been reported (<xref ref-type="bibr" rid="ref66">Iwasa et al., 2014</xref>). Head tremor is often encountered and can be associated with eye oscillations. Furthermore, nystagmus, oculomotor apraxia and exotropia were variably described in a cohort of Tunisian patients (<xref ref-type="bibr" rid="ref40">El Euch-Fayache et al., 2014</xref>). Substitutive therapy with vitamin E can prevent symptoms in presymptomatic individuals and stabilize or ameliorate the clinical picture in symptomatic patients.</p>
</sec>
</sec>
<sec id="sec6">
<title>Fundus photography and OCT parametrization of neurodegeneration in ARCAs</title>
<p>The pathologic process causing cerebellar neurodegeneration may also affect photoreceptors, ganglion cells, retinal vasculature, pigmented epithelium or axons of the optic nerve (<xref ref-type="table" rid="tab3">Table 3</xref>). A first qualitative ophthalmoscopic assessment can be obtained by fundus photography which may help to compare the two eyes following ophthalmoscopic changes over time (<xref ref-type="bibr" rid="ref13">Biousse et al., 2018</xref>). High quality fundoscopic images are also used for a quantitative assessment of retinal vasculature, retinal layers or optic nerve head structure and shape (<xref ref-type="bibr" rid="ref14">Biousse and Newman, 2016</xref>; <xref ref-type="bibr" rid="ref96">Panwar et al., 2016</xref>).</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption><p>Ocular coherence tomography assessment in the three most common ARCAs associated to mitochondrial pathway involvement.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="left" valign="top">Ganglion cells</th>
<th align="left" valign="top">Retinal fibers</th>
<th align="left" valign="top">Optic nerve</th>
<th align="left" valign="top">Macula</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2">ARSACS</td>
<td align="left" valign="top" rowspan="2">Loss</td>
<td align="left" valign="top" rowspan="2">Increased retinal peripapillary inner thickness</td>
<td align="left" valign="top">Progressive optic nerve atrophy</td>
<td align="left" valign="top" rowspan="2">Macula microcysts, Foveal hypoplasia</td>
</tr>
<tr>
<td align="left" valign="top">/</td>
</tr>
<tr>
<td align="left" valign="top">FRDA</td>
<td align="left" valign="top">Loss</td>
<td align="left" valign="top">RNFL average thickness reduced</td>
<td align="left" valign="top">Progressive neurorim pallor</td>
<td align="left" valign="top">/</td>
</tr>
<tr>
<td align="left" valign="top">SPG7</td>
<td align="left" valign="top">Loss</td>
<td align="left" valign="top">RNFL average thickness reduced, &#x003E; in temporal quadrant</td>
<td align="left" valign="top">Optic neuropathy (in rarely cases is the only manifestation)</td>
<td align="left" valign="top">/</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Digital image processing is one of the most widely used computer vision technology in biomedical engineering and various digital techniques are used to analyze retinal deposits, exudates, and microvasculature and to measure geometric features such as vessel tortuosity, branching angles, branching coefficient, vessel diameter, and fractal dimension (<xref ref-type="bibr" rid="ref103">Rajalakshmi et al., 2021</xref>). The extracted markers of fundus digital images, provide quantitative assessment of retinal topographic changes associated to various diseases (<xref ref-type="bibr" rid="ref70">Kipli et al., 2018</xref>).</p>
<p>OCT is a widely used retinal imaging technique providing high resolution cross-sectional view of retinal layers and retinal thickness. Light reflectance principles underly spectral domain OCT (SD-OCT) and multicolor OCT (MC-OCT) technology, that makes the retina and optic nerve visible at a 5- to 6-nm resolution in an imaging process that requires only 2&#x2009;min per eye (<xref ref-type="bibr" rid="ref86">Minakaran et al., 2021</xref>). Combining structural and functional (visual) information, machine learning classification, and AI methods, allows us to elaborate digital markers of retinal and optic nerve degeneration or validate OCT intra or inter-eye morpho-functional thresholds (<xref ref-type="bibr" rid="ref101">Pujari et al., 2021</xref>).</p>
<p>The further innovation introduced by MC-OCT is the use of 3 different, simultaneous laser light wavelengths to produce &#x201C;fundus photography tomograms&#x201D; of deep, mid, and inner retinal layers. MC-OCT uses ultrared (815&#x2009;nm), green (518&#x2009;nm), and blue (486&#x2009;nm) lights to reflect the retina over almost the entire visible light spectrum. These different wavelengths create focused and detailed images especially of the retinal blood vessels. The assessment of retinal vessels by MC-OCT together with the retinal GC density and peripapillary nerve fiber layer (pRNFL) measurements (which reflects the safety of optic nerves, chiasm, and optic tracts) by spectral domain OCT, allow finding out <italic>&#x201C;in vivo&#x201D;</italic> optic nerve and retinal structural changes and the inter-eye differences in acquired or genetic optic neuropathies, including those encountered in ARCAs with relevant clinical and prognostic implications.</p>
<sec id="sec7">
<title>RNFL and ganglion cells assessment</title>
<p>Optic neuropathy is frequently observed in ARCAs, particularly in those forms primarily related to damage of mitochondrial pathway such as <italic>FRDA, SPG7, ARSACS</italic>, where retinal GCs death is a specific target for mitochondrial mediated neurodegeneration in the retina (<xref ref-type="bibr" rid="ref93">Newman et al., 2023</xref>).</p>
<p>Mitochondrial optic neuropathies are a relatively homogeneous group of visual disorders characterized by preferential involvement of small axons of the papillo-macular bundle, serving central vision, color vision and high spatial frequency contrast sensitivity (<xref ref-type="bibr" rid="ref21">Carelli et al., 2004</xref>). The high vulnerability of central retinal GCs to mitochondrial damage is due to prevalent dependence of the intra-retinal axonal transport from mitochondrial metabolism. Differently from hereditary non-syndromic mitochondrial-related optic neuropathies such as LHON, the papillo-macular bundle is less affected at onset in <italic>FRDA</italic> and other mitochondrial related ARCAs, leaving visual acuity, contrast sensitivity and color vision, longer preserved than LHON. However, the advent of OCT has evidenced an early axonal damage and GCs loss in several ARCAs including FRDA. This technique also allows to monitor changes of retinal thickness over time supporting a role for these structural measures, as a marker of neurodegeneration in these diseases.</p>
<p>Neurorim pallor is clinically apparent in 30% of FRDA patients at the onset (<xref ref-type="bibr" rid="ref61">Harding, 1981</xref>; <xref ref-type="bibr" rid="ref48">Fortuna et al., 2009</xref>). Several studies (<xref ref-type="bibr" rid="ref48">Fortuna et al., 2009</xref>; <xref ref-type="bibr" rid="ref94">Noval et al., 2012</xref>; <xref ref-type="bibr" rid="ref120">Seyer et al., 2013</xref>; <xref ref-type="bibr" rid="ref33">Da&#x011F; et al., 2014</xref>) have evaluated RNFL and GC changes using OCT showing decreased average RNFL thickness, which was statistically significant in comparison to controls. Abnormal RNFL thinning in all quadrants has been reported, with a distinctive pattern of predominant involvement of superior quadrant, while macular and foveal thickness is generally preserved in these patients. Recently, FRDA was reported to be associated with the greatest degree of RNFL thinning in comparison to a range of other genetically determined ataxias. RNFL thickness in FRDA has been shown to correlate with neurological function and disability as measured with the International Cooperative Ataxia Rating Scale (ICARS). More recently, a correlation between the peripapillary RNFL and the Scale for Assessment and Rating of Ataxia (SARA) used to quantify disability was demonstrated by <xref ref-type="bibr" rid="ref97">Parkinson et al. (2018)</xref> and <xref ref-type="bibr" rid="ref106">Rojas et al. (2021)</xref>. Another significant correlation has been found between thinning of the RNFL and frataxin protein levels, leading authors to suggest the use of these two measures as biomarkers in future clinical trial design (<xref ref-type="bibr" rid="ref135">Thomas-Black et al., 2023</xref>).</p>
<p>Degenerative optic neuropathy is also reported in several families with SPG7; however, not all patients have reduced visual acuity. Optic atrophy occurred in 3/49 cases of SPG7 in a Dutch cohort; two SPG7 mutated sibs with optic atrophy manifested severe vision loss as the presenting symptom evolving to full blindness in the course of the illnesses. Post-mortem examination of one of these sibs disclosed severe atrophy affecting the optic nerves, optic chiasm and optic tracts with loss of axons, demyelination and astrogliosis (<xref ref-type="bibr" rid="ref142">van Gassen et al., 2012</xref>). In accordance with these data, employing OCT, global RNFL thinning in individuals with SPG7 has been reported in several cohorts (<xref ref-type="bibr" rid="ref147">Wiethoff et al., 2012</xref>). It has been shown that retinal fibers loss is more pronounced in the temporal quadrant (<xref ref-type="bibr" rid="ref16">Bogdanova-Mihaylova et al., 2021</xref>). Patients with severe loss of RNFL and low visual acuity may have a more complex phenotype including intellectual disability, cognitive decline, limb spasticity and cerebellar ataxia (<xref ref-type="bibr" rid="ref147">Wiethoff et al., 2012</xref>). In 65% of patients belonging to a large SPG7 family (<xref ref-type="bibr" rid="ref71">Klebe et al., 2012</xref>), authors found the homozygous Ala510Val mutation associated with optic neuropathy, present in all patients. Moreover, the same authors showed a novel missense <italic>SPG7</italic> mutation in heterozygous state (Asp411Ala) as the cause of autosomal dominant optic neuropathy in a large family, indicating that some <italic>SPG7</italic> mutations can occasionally be dominantly inherited and be an uncommon cause of isolated optic neuropathy. <italic>Paraplegin</italic> is a metalloprotease known to cleave OPA protein 1 (a mitochondrial dynamin-related protein) into two active subunits, which locate in the inner mitochondrial membrane and regulate multiple mitochondrial functions, including fusion and fission (<xref ref-type="bibr" rid="ref47">Ferreirinha et al., 2004</xref>; <xref ref-type="bibr" rid="ref81">Martinelli and Rugarli, 2010</xref>). Abnormal <italic>paraplegin</italic> function may therefore result in a damage for GCs or optic nerve axons like those commonly found in non-syndromic mitochondrial optic neuropathy.</p>
<p>In ARSACS (<xref ref-type="bibr" rid="ref59">Girard et al., 2012</xref>) the characteristic ophthalmic hallmark is an increased peripapillary inner retinal thickness, previously mis-characterized as hyper-myelinated nerve fiber layer. Conversely, visual loss is rare and unrelated to RNFL thickening (<xref ref-type="bibr" rid="ref55">Garcia-Martin et al., 2013</xref>; <xref ref-type="bibr" rid="ref97">Parkinson et al., 2018</xref>; <xref ref-type="bibr" rid="ref104">Rezende Filho et al., 2021</xref>). OCT helped to clarify the characteristic modifications of the retinal layers in ARSACS showing retinal striations or folds with sawtooth appearance, foveal hypoplasia in 100% of patients, macular microcysts, papillomacular folds and thick peripapillary RNFL. Several studies have indicated that the thickness of all retinal layers is a distinctive pattern of ARSACS suggesting a role of the <italic>SACS</italic> gene in the development of the retina and optic nerve (<xref ref-type="bibr" rid="ref57">Gazulla et al., 2011</xref>; <xref ref-type="bibr" rid="ref129">Synofzik et al., 2013</xref>). <italic>Sacsin</italic> has been confirmed to be involved in regulating mitochondrial dynamics, in promoting neurofilament assembly or resolving their bundling accumulations and modulating interactions between cytoskeletal and synaptic adhesion proteins (<xref ref-type="bibr" rid="ref18">Bradshaw et al., 2016</xref>; <xref ref-type="bibr" rid="ref107">Romano et al., 2022</xref>).</p>
</sec>
</sec>
<sec id="sec8">
<title>AI and parametrization of oculomotor data</title>
<p>Artificial intelligence (AI) is a branch of computer science seeking to simulate human intelligence in computers. AI is currently applied in medicine to accurately identify abnormalities in clinical, imaging or electrophysiological parameters and to distinguish individuals deviating from healthy controls. The term &#x201C;artificial intelligence&#x201D; includes machine learning and deep learning approaches. <italic>Machine learning</italic> is commonly described as &#x201C;a field of study that gives computers the ability to learn without being explicitly programmed.&#x201D; Characteristically, machine learning programs can modify the parameters of their algorithms by the exposure to more data, featuring in this way an adaptive response to the presented data and the ability to make predictions based on parameters related to their algorithms. <italic>Deep learning</italic> is a subset of machine learning based on artificial neural networks trying to mimic the complex computation capabilities, decision-making patterns, and neural connectivity typical of the human brain. Complex, multi-layered neural networks are assembled for allowing data to pass between nodes (like neurons) in highly connected ways, reaching increasingly non-linear transformation of the data.</p>
<p>Convolutional neural networks are capable of image recognition and classification; they are a crucial component of deep learning applications in medicine, especially in OCT imaging elaboration. The application of AI and deep learning techniques using OCT images has increased in recent years to assist clinicians in the diagnosis and management of neuroophthalmological diseases (<xref ref-type="bibr" rid="ref67">Kapoor et al., 2019</xref>; <xref ref-type="bibr" rid="ref85">Milea et al., 2020</xref>). Machine learning and deep learning are also applied in video-based eye-tracking technology using the existing front-facing cameras of smartphones and laptops to record eye movements. Machine learning models trained on eye movement features are then used to accurately identify eye abnormalities. This approach has been tested in ataxia patients where the algorithm detects saccade dysmetria (<xref ref-type="bibr" rid="ref4">Azami et al., 2022</xref>) or pursuit changes in affected subjects (<xref ref-type="bibr" rid="ref23">Chang et al., 2020</xref>) showing good performances (<xref ref-type="bibr" rid="ref4">Azami et al., 2022</xref>).</p>
</sec>
<sec sec-type="conclusions" id="sec9">
<title>Conclusion</title>
<p>In conclusion, ocular features may be considered as ideal biomarkers for disease assessment in autosomal recessive cerebellar ataxias (ARCAs). In this perspective, the quantification of eye movements changes may help localizing the cerebellar-extracerebellar networks specifically involved in ARCAs; at the same time, the quantification of structural retinal changes by OCT provides a measure of neurodegeneration particularly in those forms related to mitochondrial pathway dysfunctions. Thus, the examination of visual system may drive a possible diagnostic classification approach according to ocular features since the three common pathways underlying ARCAs, i.e., mitochondrial metabolism, DNA repair/genome stability and complex lipid metabolism, show, respectively, peculiar pattern of visual system dysfunction.</p>
<p>The recent advances of AI, the use of sensors and other embedded devices is paving the way for real-life use of digital biomarkers; among these, the oculomotor markers and OCT cannot be missing in cerebellar ataxias.</p>
</sec>
<sec sec-type="author-contributions" id="sec10">
<title>Author contributions</title>
<p>DL: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. FR: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. EP: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. AB: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. VS: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. AR: Conceptualization, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec12">
<title>Funding</title>
<p>The author (s) declare financial support was received for the research, authorship, and/or publication of this article. AR was partially supported by a grant from Fondazione Telethon (GSA22M002).</p>
</sec>
<sec sec-type="COI-statement" id="sec13">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anheim</surname> <given-names>M.</given-names></name> <name><surname>Fleury</surname> <given-names>M.</given-names></name> <name><surname>Monga</surname> <given-names>B.</given-names></name> <name><surname>Laugel</surname> <given-names>V.</given-names></name> <name><surname>Chaigne</surname> <given-names>D.</given-names></name> <name><surname>Rodier</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Epidemiological, clinical, Paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, eastern France: implications for clinical management</article-title>. <source>Neurogenetics</source> <volume>11</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10048-009-0196-y</pub-id>, PMID: <pub-id pub-id-type="pmid">19440741</pub-id></citation></ref>
<ref id="ref2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anheim</surname> <given-names>M.</given-names></name> <name><surname>Monga</surname> <given-names>B.</given-names></name> <name><surname>Fleury</surname> <given-names>M.</given-names></name> <name><surname>Charles</surname> <given-names>P.</given-names></name> <name><surname>Barbot</surname> <given-names>C.</given-names></name> <name><surname>Salih</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Ataxia with Oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients</article-title>. <source>Brain</source> <volume>132</volume>, <fpage>2688</fpage>&#x2013;<lpage>2698</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awp211</pub-id>, PMID: <pub-id pub-id-type="pmid">19696032</pub-id></citation></ref>
<ref id="ref3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asanad</surname> <given-names>S.</given-names></name> <name><surname>Tian</surname> <given-names>J. J.</given-names></name> <name><surname>Frousiakis</surname> <given-names>S.</given-names></name> <name><surname>Jiang</surname> <given-names>J. P.</given-names></name> <name><surname>Kogachi</surname> <given-names>K.</given-names></name> <name><surname>Felix</surname> <given-names>C. M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Optical coherence tomography of the retinal ganglion cell complex in Leber&#x2019;s hereditary optic neuropathy and dominant optic atrophy</article-title>. <source>Curr. Eye Res.</source> <volume>44</volume>, <fpage>638</fpage>&#x2013;<lpage>644</lpage>. doi: <pub-id pub-id-type="doi">10.1080/02713683.2019.1567792</pub-id>, PMID: <pub-id pub-id-type="pmid">30649972</pub-id></citation></ref>
<ref id="ref4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azami</surname> <given-names>H.</given-names></name> <name><surname>Chang</surname> <given-names>Z.</given-names></name> <name><surname>Arnold</surname> <given-names>S. E.</given-names></name> <name><surname>Sapiro</surname> <given-names>G.</given-names></name> <name><surname>Gupta</surname> <given-names>A. S.</given-names></name></person-group> (<year>2022</year>). <article-title>Detection of Oculomotor Dysmetria from Mobile phone video of the horizontal saccades task using signal processing and machine learning approaches</article-title>. <source>IEEE Access</source> <volume>10</volume>, <fpage>34022</fpage>&#x2013;<lpage>34031</lpage>. doi: <pub-id pub-id-type="doi">10.1109/ACCESS.2022.3156964</pub-id>, PMID: <pub-id pub-id-type="pmid">36339795</pub-id></citation></ref>
<ref id="ref5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baets</surname> <given-names>J.</given-names></name> <name><surname>Deconinck</surname> <given-names>T.</given-names></name> <name><surname>Smets</surname> <given-names>K.</given-names></name> <name><surname>Goossens</surname> <given-names>D.</given-names></name> <name><surname>van den Bergh</surname> <given-names>P.</given-names></name> <name><surname>Dahan</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Mutations in SACS cause atypical and late-onset forms of ARSACS</article-title>. <source>Neurology</source> <volume>75</volume>, <fpage>1181</fpage>&#x2013;<lpage>1188</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f4d86c</pub-id>, PMID: <pub-id pub-id-type="pmid">20876471</pub-id></citation></ref>
<ref id="ref6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baloh</surname> <given-names>R. W.</given-names></name></person-group> (<year>1978</year>). <article-title>Internuclear Ophthalmoplegia</article-title>. <source>Arch. Neurol.</source> <volume>35</volume>:<fpage>484</fpage>. doi: <pub-id pub-id-type="doi">10.1001/archneur.1978.00500320004002</pub-id></citation></ref>
<ref id="ref7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bargagli</surname> <given-names>A.</given-names></name> <name><surname>Rosini</surname> <given-names>F.</given-names></name> <name><surname>Zanca</surname> <given-names>D.</given-names></name> <name><surname>Serchi</surname> <given-names>V.</given-names></name> <name><surname>Rufa</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Ataxia with Oculomotor apraxia type 2 (AOA2): an eye movement study of two siblings</article-title>. <source>Neurol. Sci.</source> <volume>42</volume>, <fpage>3039</fpage>&#x2013;<lpage>3042</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10072-021-05206-1</pub-id>, PMID: <pub-id pub-id-type="pmid">33770309</pub-id></citation></ref>
<ref id="ref8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaudin</surname> <given-names>M.</given-names></name> <name><surname>Matilla-Due&#x00F1;as</surname> <given-names>A.</given-names></name> <name><surname>Soong</surname> <given-names>B.-W.</given-names></name> <name><surname>Pedroso</surname> <given-names>J. L.</given-names></name> <name><surname>Barsottini</surname> <given-names>O. G.</given-names></name> <name><surname>Mitoma</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>The classification of autosomal recessive cerebellar ataxias: a consensus statement from the Society for Research on the cerebellum and ataxias task force</article-title>. <source>Cerebellum</source> <volume>18</volume>, <fpage>1098</fpage>&#x2013;<lpage>1125</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-019-01052-2</pub-id>, PMID: <pub-id pub-id-type="pmid">31267374</pub-id></citation></ref>
<ref id="ref9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname> <given-names>A. E.</given-names></name> <name><surname>Vargas</surname> <given-names>W.</given-names></name> <name><surname>Pearson</surname> <given-names>T. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Ataxia with vitamin e deficiency may present with cervical dystonia</article-title>. <source>Tremor Other Hyperkin Movements</source> <volume>6</volume>:<fpage>298</fpage>. doi: <pub-id pub-id-type="doi">10.5334/tohm.298</pub-id></citation></ref>
<ref id="ref10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname> <given-names>C. L.</given-names></name> <name><surname>La Spada</surname> <given-names>A. R.</given-names></name></person-group> (<year>2021</year>). <article-title>SUMOylated Senataxin functions in genome stability, RNA degradation, and stress granule disassembly, and is linked with inherited ataxia and motor neuron disease</article-title>. <source>Mol Genet Genomic Med</source> <volume>9</volume>:<fpage>e1745</fpage>. doi: <pub-id pub-id-type="doi">10.1002/mgg3.1745</pub-id>, PMID: <pub-id pub-id-type="pmid">34263556</pub-id></citation></ref>
<ref id="ref11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benomar</surname> <given-names>A.</given-names></name> <name><surname>Yahyaoui</surname> <given-names>M.</given-names></name> <name><surname>Meggouh</surname> <given-names>F.</given-names></name> <name><surname>Bouhouche</surname> <given-names>A.</given-names></name> <name><surname>Boutchich</surname> <given-names>M.</given-names></name> <name><surname>Bouslam</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Clinical comparison between AVED patients with 744 Del a mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families</article-title>. <source>J. Neurol. Sci.</source> <volume>198</volume>, <fpage>25</fpage>&#x2013;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0022-510X(02)00057-6</pub-id></citation></ref>
<ref id="ref12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname> <given-names>L.</given-names></name> <name><surname>Meng</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>M.</given-names></name> <name><surname>Li</surname> <given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment</article-title>. <source>Mol. Cancer</source> <volume>18</volume>:<fpage>169</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-019-1100-5</pub-id>, PMID: <pub-id pub-id-type="pmid">31767017</pub-id></citation></ref>
<ref id="ref13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biousse</surname> <given-names>V.</given-names></name> <name><surname>Bruce</surname> <given-names>B. B.</given-names></name> <name><surname>Newman</surname> <given-names>N. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Ophthalmoscopy in the 21st century</article-title>. <source>Neurology</source> <volume>90</volume>, <fpage>167</fpage>&#x2013;<lpage>175</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000004868</pub-id>, PMID: <pub-id pub-id-type="pmid">29273687</pub-id></citation></ref>
<ref id="ref14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biousse</surname> <given-names>V.</given-names></name> <name><surname>Newman</surname> <given-names>N. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Diagnosis and clinical features of common optic neuropathies</article-title>. <source>Lancet Neurol</source> <volume>15</volume>, <fpage>1355</fpage>&#x2013;<lpage>1367</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(16)30237-X</pub-id></citation></ref>
<ref id="ref15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Biousse</surname> <given-names>V.</given-names></name> <name><surname>Newman</surname> <given-names>N. J.</given-names></name> <name><surname>Najjar</surname> <given-names>R. P.</given-names></name> <name><surname>Vasseneix</surname> <given-names>C.</given-names></name> <name><surname>Xu</surname> <given-names>X.</given-names></name> <name><surname>Ting</surname> <given-names>D. S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Optic disc classification by deep learning versus expert Neuro-ophthalmologists</article-title>. <source>Ann. Neurol.</source> <volume>88</volume>, <fpage>785</fpage>&#x2013;<lpage>795</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.25839</pub-id>, PMID: <pub-id pub-id-type="pmid">32621348</pub-id></citation></ref>
<ref id="ref16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bogdanova-Mihaylova</surname> <given-names>P.</given-names></name> <name><surname>Plapp</surname> <given-names>H. M.</given-names></name> <name><surname>Chen</surname> <given-names>H.</given-names></name> <name><surname>Early</surname> <given-names>A.</given-names></name> <name><surname>Cassidy</surname> <given-names>L.</given-names></name> <name><surname>Walsh</surname> <given-names>R. A.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Longitudinal assessment using optical coherence tomography in patients with Friedreich&#x2019;s ataxia</article-title>. <source>Tomography</source> <volume>7</volume>, <fpage>915</fpage>&#x2013;<lpage>931</lpage>. doi: <pub-id pub-id-type="doi">10.3390/tomography7040076</pub-id>, PMID: <pub-id pub-id-type="pmid">34941648</pub-id></citation></ref>
<ref id="ref17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonifert</surname> <given-names>T.</given-names></name> <name><surname>Karle</surname> <given-names>K. N.</given-names></name> <name><surname>Tonagel</surname> <given-names>F.</given-names></name> <name><surname>Batra</surname> <given-names>M.</given-names></name> <name><surname>Wilhelm</surname> <given-names>C.</given-names></name> <name><surname>Theurer</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Pure and Syndromic optic atrophy explained by deep Intronic OPA1 mutations and an Intralocus modifier</article-title>. <source>Brain</source> <volume>137</volume>, <fpage>2164</fpage>&#x2013;<lpage>2177</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awu165</pub-id>, PMID: <pub-id pub-id-type="pmid">24970096</pub-id></citation></ref>
<ref id="ref18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname> <given-names>T. Y.</given-names></name> <name><surname>Romano</surname> <given-names>L. E. L.</given-names></name> <name><surname>Duncan</surname> <given-names>E. J.</given-names></name> <name><surname>Nethisinghe</surname> <given-names>S.</given-names></name> <name><surname>Abeti</surname> <given-names>R.</given-names></name> <name><surname>Michael</surname> <given-names>G. J.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>A reduction in Drp1-mediated fission compromises mitochondrial health in autosomal recessive spastic ataxia of Charlevoix Saguenay</article-title>. <source>Hum. Mol. Genet.</source> <volume>25</volume>, <fpage>3232</fpage>&#x2013;<lpage>3244</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddw173</pub-id>, PMID: <pub-id pub-id-type="pmid">27288452</pub-id></citation></ref>
<ref id="ref19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caglayan</surname> <given-names>A. O.</given-names></name> <name><surname>Gumus</surname> <given-names>H.</given-names></name> <name><surname>Sandford</surname> <given-names>E.</given-names></name> <name><surname>Kubisiak</surname> <given-names>T. L.</given-names></name> <name><surname>Ma</surname> <given-names>Q.</given-names></name> <name><surname>Ozel</surname> <given-names>A. B.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>COQ4 mutation leads to childhood-onset ataxia improved by CoQ10 administration</article-title>. <source>Cerebellum</source> <volume>18</volume>, <fpage>665</fpage>&#x2013;<lpage>669</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-019-01011-x</pub-id>, PMID: <pub-id pub-id-type="pmid">30847826</pub-id></citation></ref>
<ref id="ref20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caldecott</surname> <given-names>K. W.</given-names></name></person-group> (<year>2003</year>). <article-title>DNA single-Strand break repair and Spinocerebellar ataxia</article-title>. <source>Cell</source> <volume>112</volume>, <fpage>7</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(02)01247-3</pub-id></citation></ref>
<ref id="ref21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carelli</surname> <given-names>V.</given-names></name> <name><surname>Ross-Cisneros</surname> <given-names>F. N.</given-names></name> <name><surname>Sadun</surname> <given-names>A. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Mitochondrial dysfunction as a cause of optic neuropathies</article-title>. <source>Prog. Retin. Eye Res.</source> <volume>23</volume>, <fpage>53</fpage>&#x2013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.preteyeres.2003.10.003</pub-id></citation></ref>
<ref id="ref22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casari</surname> <given-names>G.</given-names></name> <name><surname>de Fusco</surname> <given-names>M.</given-names></name> <name><surname>Ciarmatori</surname> <given-names>S.</given-names></name> <name><surname>Zeviani</surname> <given-names>M.</given-names></name> <name><surname>Mora</surname> <given-names>M.</given-names></name> <name><surname>Fernandez</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>1998</year>). <article-title>Spastic paraplegia and OXPHOS impairment caused by mutations in Paraplegin, a nuclear-encoded mitochondrial Metalloprotease</article-title>. <source>Cell</source> <volume>93</volume>, <fpage>973</fpage>&#x2013;<lpage>983</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81203-9</pub-id>, PMID: <pub-id pub-id-type="pmid">9635427</pub-id></citation></ref>
<ref id="ref23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>Z.</given-names></name> <name><surname>Chen</surname> <given-names>Z.</given-names></name> <name><surname>Stephen</surname> <given-names>C. D.</given-names></name> <name><surname>Schmahmann</surname> <given-names>J. D.</given-names></name> <name><surname>Wu</surname> <given-names>H.-T.</given-names></name> <name><surname>Sapiro</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Accurate detection of cerebellar smooth pursuit eye movement abnormalities via Mobile phone video and machine learning</article-title>. <source>Sci. Rep.</source> <volume>10</volume>:<fpage>18641</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-75661-x</pub-id>, PMID: <pub-id pub-id-type="pmid">33122811</pub-id></citation></ref>
<ref id="ref24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Charif</surname> <given-names>M.</given-names></name> <name><surname>Chevrollier</surname> <given-names>A.</given-names></name> <name><surname>Gueguen</surname> <given-names>N.</given-names></name> <name><surname>Bris</surname> <given-names>C.</given-names></name> <name><surname>Gouden&#x00E8;ge</surname> <given-names>D.</given-names></name> <name><surname>Desquiret-Dumas</surname> <given-names>V.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Mutations in the M-AAA proteases AFG3L2 and SPG7 are causing isolated dominant optic atrophy</article-title>. <source>Neurology</source> <volume>6</volume>:<fpage>428</fpage>. doi: <pub-id pub-id-type="doi">10.1212/NXG.0000000000000428</pub-id></citation></ref>
<ref id="ref25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname> <given-names>Y.</given-names></name> <name><surname>Komori</surname> <given-names>H.</given-names></name> <name><surname>Takei</surname> <given-names>S.</given-names></name> <name><surname>Hasegawa-Ishii</surname> <given-names>S.</given-names></name> <name><surname>Kawamura</surname> <given-names>N.</given-names></name> <name><surname>Adachi</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Niemann-Pick disease type &#x003C;scp&#x003E;C&#x003C;/Scp&#x003E; 1 predominantly involving the Frontotemporal region, with cortical and brainstem &#x003C;scp&#x003E;L&#x003C;/Scp&#x003E; Ewy bodies: an autopsy case</article-title>. <source>Neuropathology</source> <volume>34</volume>, <fpage>49</fpage>&#x2013;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1111/neup.12047</pub-id>, PMID: <pub-id pub-id-type="pmid">23711246</pub-id></citation></ref>
<ref id="ref26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coarelli</surname> <given-names>G.</given-names></name> <name><surname>Schule</surname> <given-names>R.</given-names></name> <name><surname>van de Warrenburg</surname> <given-names>B. P. C.</given-names></name> <name><surname>de Jonghe</surname> <given-names>P.</given-names></name> <name><surname>Ewenczyk</surname> <given-names>C.</given-names></name> <name><surname>Martinuzzi</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Loss of Paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with SPG7</article-title>. <source>Neurology</source> <volume>92</volume>, <fpage>e2679</fpage>&#x2013;<lpage>e2690</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000007606</pub-id>, PMID: <pub-id pub-id-type="pmid">31068484</pub-id></citation></ref>
<ref id="ref27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname> <given-names>Z. J.</given-names></name> <name><surname>Kuntzelman</surname> <given-names>K. M.</given-names></name> <name><surname>Dodd</surname> <given-names>M. D.</given-names></name> <name><surname>Johnson</surname> <given-names>M. R.</given-names></name></person-group> (<year>2021</year>). <article-title>Convolutional neural networks can decode eye movement data: a black box approach to predicting task from eye movements</article-title>. <source>J. Vis.</source> <volume>21</volume>:<fpage>9</fpage>. doi: <pub-id pub-id-type="doi">10.1167/jov.21.7.9</pub-id>, PMID: <pub-id pub-id-type="pmid">34264288</pub-id></citation></ref>
<ref id="ref28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname> <given-names>A. G.</given-names></name> <name><surname>Troedson</surname> <given-names>C.</given-names></name> <name><surname>Wilson</surname> <given-names>M.</given-names></name> <name><surname>Procopis</surname> <given-names>P. G.</given-names></name> <name><surname>Li</surname> <given-names>F.-Y.</given-names></name> <name><surname>Brundage</surname> <given-names>E. K.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Application of oligonucleotide Array CGH in the detection of a large intragenic deletion in POLG associated with Alpers syndrome</article-title>. <source>Mitochondrion</source> <volume>11</volume>, <fpage>104</fpage>&#x2013;<lpage>107</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mito.2010.07.012</pub-id>, PMID: <pub-id pub-id-type="pmid">20708716</pub-id></citation></ref>
<ref id="ref29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname> <given-names>A.</given-names></name> <name><surname>Simone</surname> <given-names>R.</given-names></name> <name><surname>Sullivan</surname> <given-names>R.</given-names></name> <name><surname>Vandrovcova</surname> <given-names>J.</given-names></name> <name><surname>Tariq</surname> <given-names>H.</given-names></name> <name><surname>Yau</surname> <given-names>W. Y.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Biallelic expansion of an Intronic repeat in RFC1 is a common cause of late-onset ataxia</article-title>. <source>Nat. Genet.</source> <volume>51</volume>, <fpage>649</fpage>&#x2013;<lpage>658</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41588-019-0372-4</pub-id></citation></ref>
<ref id="ref30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Criscuolo</surname> <given-names>C.</given-names></name> <name><surname>Procaccini</surname> <given-names>C.</given-names></name> <name><surname>Meschini</surname> <given-names>M. C.</given-names></name> <name><surname>Cianflone</surname> <given-names>A.</given-names></name> <name><surname>Carbone</surname> <given-names>R.</given-names></name> <name><surname>Doccini</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Powerhouse failure and oxidative damage in autosomal recessive spastic ataxia of Charlevoix-Saguenay</article-title>. <source>J. Neurol.</source> <volume>262</volume>, <fpage>2755</fpage>&#x2013;<lpage>2763</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-015-7911-4</pub-id>, PMID: <pub-id pub-id-type="pmid">26530509</pub-id></citation></ref>
<ref id="ref31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cruysberg</surname> <given-names>J. R. M.</given-names></name> <name><surname>Wevers</surname> <given-names>R. A.</given-names></name> <name><surname>van Engelen</surname> <given-names>B. G. M.</given-names></name> <name><surname>Pinckers</surname> <given-names>A.</given-names></name> <name><surname>van Spreeken</surname> <given-names>A.</given-names></name> <name><surname>Tolboom</surname> <given-names>J. J. M.</given-names></name></person-group> (<year>1995</year>). <article-title>Ocular and systemic manifestations of Cerebrotendinous Xanthomatosis</article-title>. <source>Am J. Ophthalmol.</source> <volume>120</volume>, <fpage>597</fpage>&#x2013;<lpage>604</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0002-9394(14)72206-8</pub-id>, PMID: <pub-id pub-id-type="pmid">7485361</pub-id></citation></ref>
<ref id="ref32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cullen</surname> <given-names>J. K.</given-names></name> <name><surname>Abdul Murad</surname> <given-names>N.</given-names></name> <name><surname>Yeo</surname> <given-names>A.</given-names></name> <name><surname>McKenzie</surname> <given-names>M.</given-names></name> <name><surname>Ward</surname> <given-names>M.</given-names></name> <name><surname>Chong</surname> <given-names>K. L.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>AarF domain containing kinase 3 (ADCK3) mutant cells display signs of oxidative stress, defects in mitochondrial homeostasis and Lysosomal accumulation</article-title>. <source>PLoS One</source> <volume>11</volume>:<fpage>e0148213</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0148213</pub-id>, PMID: <pub-id pub-id-type="pmid">26866375</pub-id></citation></ref>
<ref id="ref33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Da&#x011F;</surname> <given-names>E.</given-names></name> <name><surname>&#x00D6;rnek</surname> <given-names>N.</given-names></name> <name><surname>&#x00D6;rnek</surname> <given-names>K.</given-names></name> <name><surname>Erbah&#x00E7;eci-Timur</surname> <given-names>I. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Optical coherence tomography and visual field findings in patients with Friedreich ataxia</article-title>. <source>J. Neuroophthalmol.</source> <volume>34</volume>, <fpage>118</fpage>&#x2013;<lpage>121</lpage>. doi: <pub-id pub-id-type="doi">10.1097/WNO.0000000000000068</pub-id>, PMID: <pub-id pub-id-type="pmid">24275983</pub-id></citation></ref>
<ref id="ref34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Date</surname> <given-names>H.</given-names></name> <name><surname>Onodera</surname> <given-names>O.</given-names></name> <name><surname>Tanaka</surname> <given-names>H.</given-names></name> <name><surname>Iwabuchi</surname> <given-names>K.</given-names></name> <name><surname>Uekawa</surname> <given-names>K.</given-names></name> <name><surname>Igarashi</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2001</year>). <article-title>Early-onset ataxia with ocular motor apraxia and Hypoalbuminemia is caused by mutations in a new HIT superfamily gene</article-title>. <source>Nat. Genet.</source> <volume>29</volume>, <fpage>184</fpage>&#x2013;<lpage>188</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng1001-184</pub-id>, PMID: <pub-id pub-id-type="pmid">11586299</pub-id></citation></ref>
<ref id="ref35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Bot</surname> <given-names>S. T.</given-names></name> <name><surname>Willemsen</surname> <given-names>M. A. A. P.</given-names></name> <name><surname>Vermeer</surname> <given-names>S.</given-names></name> <name><surname>Kremer</surname> <given-names>H. P. H.</given-names></name> <name><surname>van de Warrenburg</surname> <given-names>B. P. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Reviewing the genetic causes of spastic-ataxias</article-title>. <source>Neurology</source> <volume>79</volume>, <fpage>1507</fpage>&#x2013;<lpage>1514</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0b013e31826d5fb0</pub-id></citation></ref>
<ref id="ref36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delatycki</surname> <given-names>M. B.</given-names></name> <name><surname>Bidichandani</surname> <given-names>S. I.</given-names></name></person-group> (<year>2019</year>). <article-title>Friedreich ataxia-pathogenesis and implications for therapies</article-title>. <source>Neurobiol. Dis.</source> <volume>132</volume>:<fpage>104606</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2019.104606</pub-id>, PMID: <pub-id pub-id-type="pmid">31494282</pub-id></citation></ref>
<ref id="ref37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>di Bella</surname> <given-names>D.</given-names></name> <name><surname>Lazzaro</surname> <given-names>F.</given-names></name> <name><surname>Brusco</surname> <given-names>A.</given-names></name> <name><surname>Plumari</surname> <given-names>M.</given-names></name> <name><surname>Battaglia</surname> <given-names>G.</given-names></name> <name><surname>Pastore</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28</article-title>. <source>Nat. Genet.</source> <volume>42</volume>, <fpage>313</fpage>&#x2013;<lpage>321</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng.544</pub-id>, PMID: <pub-id pub-id-type="pmid">20208537</pub-id></citation></ref>
<ref id="ref38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dotti</surname> <given-names>M. T.</given-names></name> <name><surname>Rufa</surname> <given-names>A.</given-names></name> <name><surname>Federico</surname> <given-names>A.</given-names></name></person-group> (<year>2001</year>). <article-title>Cerebrotendinous Xanthomatosis: heterogeneity of clinical phenotype with evidence of previously Undescribed ophthalmological findings</article-title>. <source>J. Inherit. Metab. Dis.</source> <volume>24</volume>, <fpage>696</fpage>&#x2013;<lpage>706</lpage>. doi: <pub-id pub-id-type="doi">10.1023/A:1012981019336</pub-id>, PMID: <pub-id pub-id-type="pmid">11804206</pub-id></citation></ref>
<ref id="ref39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dupr&#x00E9;</surname> <given-names>M.</given-names></name> <name><surname>Hermann</surname> <given-names>R.</given-names></name> <name><surname>Froment Tilikete</surname> <given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Update on cerebellar ataxia with neuropathy and bilateral vestibular Areflexia syndrome (CANVAS)</article-title>. <source>Cerebellum</source> <volume>20</volume>, <fpage>687</fpage>&#x2013;<lpage>700</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-020-01192-w</pub-id>, PMID: <pub-id pub-id-type="pmid">33011895</pub-id></citation></ref>
<ref id="ref40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El Euch-Fayache</surname> <given-names>G.</given-names></name> <name><surname>Bouhlal</surname> <given-names>Y.</given-names></name> <name><surname>Amouri</surname> <given-names>R.</given-names></name> <name><surname>Feki</surname> <given-names>M.</given-names></name> <name><surname>Hentati</surname> <given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency</article-title>. <source>Brain</source> <volume>137</volume>, <fpage>402</fpage>&#x2013;<lpage>410</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awt339</pub-id>, PMID: <pub-id pub-id-type="pmid">24369383</pub-id></citation></ref>
<ref id="ref41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emir</surname> <given-names>U. E.</given-names></name> <name><surname>Sood</surname> <given-names>J.</given-names></name> <name><surname>Chiew</surname> <given-names>M.</given-names></name> <name><surname>Thomas</surname> <given-names>M. A.</given-names></name> <name><surname>Lane</surname> <given-names>S. P.</given-names></name></person-group> (<year>2021</year>). <article-title>High-resolution metabolic mapping of the cerebellum using 2D zoom magnetic resonance spectroscopic imaging</article-title>. <source>Magn. Reson. Med.</source> <volume>85</volume>, <fpage>2349</fpage>&#x2013;<lpage>2358</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mrm.28614</pub-id>, PMID: <pub-id pub-id-type="pmid">33283917</pub-id></citation></ref>
<ref id="ref42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Estrada-Cuzcano</surname> <given-names>A.</given-names></name> <name><surname>Martin</surname> <given-names>S.</given-names></name> <name><surname>Chamova</surname> <given-names>T.</given-names></name> <name><surname>Synofzik</surname> <given-names>M.</given-names></name> <name><surname>Timmann</surname> <given-names>D.</given-names></name> <name><surname>Holemans</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78)</article-title>. <source>Brain</source> <volume>140</volume>, <fpage>287</fpage>&#x2013;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/aww307</pub-id>, PMID: <pub-id pub-id-type="pmid">28137957</pub-id></citation></ref>
<ref id="ref43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fahey</surname> <given-names>M. C.</given-names></name> <name><surname>Cremer</surname> <given-names>P. D.</given-names></name> <name><surname>Aw</surname> <given-names>S. T.</given-names></name> <name><surname>Millist</surname> <given-names>L.</given-names></name> <name><surname>Todd</surname> <given-names>M. J.</given-names></name> <name><surname>White</surname> <given-names>O. B.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia</article-title>. <source>Brain</source> <volume>131</volume>, <fpage>1035</fpage>&#x2013;<lpage>1045</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awm323</pub-id>, PMID: <pub-id pub-id-type="pmid">18238798</pub-id></citation></ref>
<ref id="ref44"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Federico</surname> <given-names>A.</given-names></name> <name><surname>Gallus</surname> <given-names>G. N.</given-names></name></person-group> (<year>2022</year>). &#x201C;<article-title>Cerebrotendinous Xanthomatosis</article-title>&#x201D; in <source>Gene Reviews&#x00AE;</source>. eds. <person-group person-group-type="editor"><name><surname>Adam</surname> <given-names>M. P.</given-names></name> <name><surname>Feldman</surname> <given-names>J.</given-names></name> <name><surname>Mirzaa</surname> <given-names>G. M.</given-names></name> <name><surname>Pagon</surname> <given-names>R. A.</given-names></name> <name><surname>Wallace</surname> <given-names>S. E.</given-names></name></person-group> (<publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington</publisher-name>)</citation></ref>
<ref id="ref45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Federighi</surname> <given-names>P.</given-names></name> <name><surname>Ramat</surname> <given-names>S.</given-names></name> <name><surname>Rosini</surname> <given-names>F.</given-names></name> <name><surname>Pretegiani</surname> <given-names>E.</given-names></name> <name><surname>Federico</surname> <given-names>A.</given-names></name> <name><surname>Rufa</surname> <given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Characteristic eye movements in ataxia-telangiectasia-like disorder: an explanatory hypothesis</article-title>. <source>Front. Neurol.</source> <volume>8</volume>:<fpage>596</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2017.00596</pub-id>, PMID: <pub-id pub-id-type="pmid">29170652</pub-id></citation></ref>
<ref id="ref46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Capetillo</surname> <given-names>O.</given-names></name> <name><surname>Lee</surname> <given-names>A.</given-names></name> <name><surname>Nussenzweig</surname> <given-names>M.</given-names></name> <name><surname>Nussenzweig</surname> <given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>H2AX: the histone Guardian of the genome</article-title>. <source>DNA Repair</source> <volume>3</volume>, <fpage>959</fpage>&#x2013;<lpage>967</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.dnarep.2004.03.024</pub-id>, PMID: <pub-id pub-id-type="pmid">15279782</pub-id></citation></ref>
<ref id="ref47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferreirinha</surname> <given-names>F.</given-names></name> <name><surname>Quattrini</surname> <given-names>A.</given-names></name> <name><surname>Pirozzi</surname> <given-names>M.</given-names></name> <name><surname>Valsecchi</surname> <given-names>V.</given-names></name> <name><surname>Dina</surname> <given-names>G.</given-names></name> <name><surname>Broccoli</surname> <given-names>V.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Axonal degeneration in Paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport</article-title>. <source>J. Clin. Investig.</source> <volume>113</volume>, <fpage>231</fpage>&#x2013;<lpage>242</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI200420138</pub-id>, PMID: <pub-id pub-id-type="pmid">14722615</pub-id></citation></ref>
<ref id="ref48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fortuna</surname> <given-names>F.</given-names></name> <name><surname>Barboni</surname> <given-names>P.</given-names></name> <name><surname>Liguori</surname> <given-names>R.</given-names></name> <name><surname>Valentino</surname> <given-names>M. L.</given-names></name> <name><surname>Savini</surname> <given-names>G.</given-names></name> <name><surname>Gellera</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Visual system involvement in patients with Friedreich&#x2019;s ataxia</article-title>. <source>Brain</source> <volume>132</volume>, <fpage>116</fpage>&#x2013;<lpage>123</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awn269</pub-id>, PMID: <pub-id pub-id-type="pmid">18931386</pub-id></citation></ref>
<ref id="ref49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname> <given-names>S. F.</given-names></name> <name><surname>Brennand</surname> <given-names>C.</given-names></name> <name><surname>Chiang</surname> <given-names>J.</given-names></name> <name><surname>DeBarber</surname> <given-names>A.</given-names></name> <name><surname>del Monte</surname> <given-names>M. A.</given-names></name> <name><surname>Duell</surname> <given-names>P. B.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Prevalence of Cerebrotendinous Xanthomatosis among patients diagnosed with acquired juvenile-onset idiopathic bilateral cataracts</article-title>. <source>JAMA Ophthalmol</source> <volume>137</volume>, <fpage>1312</fpage>&#x2013;<lpage>1316</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2019.3639</pub-id>, PMID: <pub-id pub-id-type="pmid">31536098</pub-id></citation></ref>
<ref id="ref50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frismand</surname> <given-names>S.</given-names></name> <name><surname>Salem</surname> <given-names>H.</given-names></name> <name><surname>Panouilleres</surname> <given-names>M.</given-names></name> <name><surname>P&#x00E9;lisson</surname> <given-names>D.</given-names></name> <name><surname>Jacobs</surname> <given-names>S.</given-names></name> <name><surname>Vighetto</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>MRI findings in AOA2: cerebellar atrophy and abnormal iron detection in dentate nucleus</article-title>. <source>Neuro Image Clin</source> <volume>2</volume>, <fpage>542</fpage>&#x2013;<lpage>548</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nicl.2013.03.018</pub-id></citation></ref>
<ref id="ref51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furman</surname> <given-names>J. M.</given-names></name> <name><surname>Perlman</surname> <given-names>S.</given-names></name> <name><surname>Baloh</surname> <given-names>R. W.</given-names></name></person-group> (<year>1983</year>). <article-title>Eye movements in Friedreich&#x2019;s ataxia</article-title>. <source>Arch. Neurol.</source> <volume>40</volume>, <fpage>343</fpage>&#x2013;<lpage>346</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archneur.1983.04050060043006</pub-id></citation></ref>
<ref id="ref52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabsi</surname> <given-names>S.</given-names></name> <name><surname>Gouider-Khouja</surname> <given-names>N.</given-names></name> <name><surname>Belal</surname> <given-names>S.</given-names></name> <name><surname>Fki</surname> <given-names>M.</given-names></name> <name><surname>Kefi</surname> <given-names>M.</given-names></name> <name><surname>Turki</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2001</year>). <article-title>Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency</article-title>. <source>Eur. J. Neurol.</source> <volume>8</volume>, <fpage>477</fpage>&#x2013;<lpage>481</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1468-1331.2001.00273.x</pub-id>, PMID: <pub-id pub-id-type="pmid">11554913</pub-id></citation></ref>
<ref id="ref53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galatolo</surname> <given-names>D.</given-names></name> <name><surname>de Michele</surname> <given-names>G.</given-names></name> <name><surname>Silvestri</surname> <given-names>G.</given-names></name> <name><surname>Leuzzi</surname> <given-names>V.</given-names></name> <name><surname>Casali</surname> <given-names>C.</given-names></name> <name><surname>Musumeci</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Ngs in hereditary ataxia: when rare becomes frequent</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>:<fpage>8490</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22168490</pub-id>, PMID: <pub-id pub-id-type="pmid">34445196</pub-id></citation></ref>
<ref id="ref54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garces</surname> <given-names>P.</given-names></name> <name><surname>Antoniades</surname> <given-names>C. A.</given-names></name> <name><surname>Sobanska</surname> <given-names>A.</given-names></name> <name><surname>Kovacs</surname> <given-names>N.</given-names></name> <name><surname>Ying</surname> <given-names>S. H.</given-names></name> <name><surname>Gupta</surname> <given-names>A. S.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Quantitative Oculomotor assessment in hereditary ataxia: systematic review and consensus by the ataxia global initiative working group on digital-motor biomarkers</article-title>. <source>Cerebellum</source>. doi: <pub-id pub-id-type="doi">10.1007/s12311-023-01559-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37117990</pub-id></citation></ref>
<ref id="ref55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Martin</surname> <given-names>E.</given-names></name> <name><surname>Pablo</surname> <given-names>L. E.</given-names></name> <name><surname>Gazulla</surname> <given-names>J.</given-names></name> <name><surname>Polo</surname> <given-names>V.</given-names></name> <name><surname>Ferreras</surname> <given-names>A.</given-names></name> <name><surname>Larrosa</surname> <given-names>J. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Retinal nerve fibre layer thickness in ARSACS: myelination or hypertrophy?</article-title> <source>Br. J. Ophthalmol.</source> <volume>97</volume>, <fpage>238</fpage>&#x2013;<lpage>241</lpage>. doi: <pub-id pub-id-type="doi">10.1136/bjophthalmol-2012-302309</pub-id>, PMID: <pub-id pub-id-type="pmid">23077228</pub-id></citation></ref>
<ref id="ref56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gatti</surname> <given-names>R. A.</given-names></name> <name><surname>Tward</surname> <given-names>A.</given-names></name> <name><surname>Concannon</surname> <given-names>P.</given-names></name></person-group> (<year>1999</year>). <article-title>Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations</article-title>. <source>Mol. Genet. Metab.</source> <volume>68</volume>, <fpage>419</fpage>&#x2013;<lpage>423</lpage>. doi: <pub-id pub-id-type="doi">10.1006/mgme.1999.2942</pub-id>, PMID: <pub-id pub-id-type="pmid">10607471</pub-id></citation></ref>
<ref id="ref57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gazulla</surname> <given-names>J.</given-names></name> <name><surname>Vela</surname> <given-names>A. C.</given-names></name> <name><surname>Mar&#x00ED;n</surname> <given-names>M. A.</given-names></name> <name><surname>Pablo</surname> <given-names>L.</given-names></name> <name><surname>Santorelli</surname> <given-names>F. M.</given-names></name> <name><surname>Benavente</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Is the ataxia of Charlevoix-Saguenay a developmental disease?</article-title> <source>Med. Hypotheses</source> <volume>77</volume>, <fpage>347</fpage>&#x2013;<lpage>352</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mehy.2011.05.011</pub-id>, PMID: <pub-id pub-id-type="pmid">21665375</pub-id></citation></ref>
<ref id="ref58"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Giorgio</surname> <given-names>C.</given-names></name> <name><surname>Roberto</surname> <given-names>M.</given-names></name></person-group>. (<year>2018</year>). <article-title>Spastic paraplegia 7</article-title>. <source>GeneReviews&#x00AE;</source>. Eds. <person-group person-group-type="editor"><name><surname>Adam</surname> <given-names>M. P.</given-names></name> <etal/></person-group>. <publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington</publisher-name>.</citation></ref>
<ref id="ref59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname> <given-names>M.</given-names></name> <name><surname>Larivi&#x00E8;re</surname> <given-names>R.</given-names></name> <name><surname>Parfitt</surname> <given-names>D. A.</given-names></name> <name><surname>Deane</surname> <given-names>E. C.</given-names></name> <name><surname>Gaudet</surname> <given-names>R.</given-names></name> <name><surname>Nossova</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>109</volume>, <fpage>1661</fpage>&#x2013;<lpage>1666</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1113166109</pub-id>, PMID: <pub-id pub-id-type="pmid">22307627</pub-id></citation></ref>
<ref id="ref60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guillain</surname> <given-names>G.</given-names></name> <name><surname>Bertrand</surname> <given-names>I.</given-names></name> <name><surname>Godet-Guillain</surname> <given-names>J.</given-names></name></person-group> (<year>1942</year>). <article-title>Etude Anatomo-Clinique d&#x2019;un Cas de Cholest&#x00E9;rinose C&#x00E9;r&#x00E9;brale</article-title>. <source>Arch Neurol</source> <volume>74</volume>, <fpage>249</fpage>&#x2013;<lpage>263</lpage>.</citation></ref>
<ref id="ref61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>A. E.</given-names></name></person-group> (<year>1981</year>). <article-title>FRIEDREICH&#x2019;S ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic CRITERIA and INTRAFAMILIAL clustering of clinical features</article-title>. <source>Brain</source> <volume>104</volume>, <fpage>589</fpage>&#x2013;<lpage>620</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/104.3.589</pub-id>, PMID: <pub-id pub-id-type="pmid">7272714</pub-id></citation></ref>
<ref id="ref62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewamadduma</surname> <given-names>C. A.</given-names></name> <name><surname>Hoggard</surname> <given-names>N.</given-names></name> <name><surname>O&#x2019;Malley</surname> <given-names>R.</given-names></name> <name><surname>Robinson</surname> <given-names>M. K.</given-names></name> <name><surname>Beauchamp</surname> <given-names>N. J.</given-names></name> <name><surname>Segamogaite</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Novel genotype-phenotype and MRI correlations in a large cohort of patients with SPG7 mutations</article-title>. <source>Neurol Genet</source> <volume>4</volume>:<fpage>e279</fpage>. doi: <pub-id pub-id-type="doi">10.1212/NXG.0000000000000279</pub-id>, PMID: <pub-id pub-id-type="pmid">30533525</pub-id></citation></ref>
<ref id="ref63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hocking</surname> <given-names>D. R.</given-names></name> <name><surname>Fielding</surname> <given-names>J.</given-names></name> <name><surname>Corben</surname> <given-names>L. A.</given-names></name> <name><surname>Cremer</surname> <given-names>P. D.</given-names></name> <name><surname>Millist</surname> <given-names>L.</given-names></name> <name><surname>White</surname> <given-names>O. B.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Ocular motor fixation deficits in Friedreich ataxia</article-title>. <source>Cerebellum</source> <volume>9</volume>, <fpage>411</fpage>&#x2013;<lpage>418</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-010-0178-5</pub-id>, PMID: <pub-id pub-id-type="pmid">20467851</pub-id></citation></ref>
<ref id="ref64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname> <given-names>R.</given-names></name> <name><surname>Czermin</surname> <given-names>B.</given-names></name> <name><surname>Gulati</surname> <given-names>S.</given-names></name> <name><surname>Demuth</surname> <given-names>S.</given-names></name> <name><surname>Houge</surname> <given-names>G.</given-names></name> <name><surname>Pyle</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Adult-onset cerebellar ataxia due to mutations in CABC1/ADCK3</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source> <volume>83</volume>, <fpage>174</fpage>&#x2013;<lpage>178</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2011-301258</pub-id>, PMID: <pub-id pub-id-type="pmid">22036850</pub-id></citation></ref>
<ref id="ref65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imrie</surname> <given-names>J.</given-names></name> <name><surname>Dasgupta</surname> <given-names>S.</given-names></name> <name><surname>Besley</surname> <given-names>G. T. N.</given-names></name> <name><surname>Harris</surname> <given-names>C.</given-names></name> <name><surname>Heptinstall</surname> <given-names>L.</given-names></name> <name><surname>Knight</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>The natural history of Niemann&#x2013;pick disease type C in the UK</article-title>. <source>J. Inherit. Metab. Dis.</source> <volume>30</volume>, <fpage>51</fpage>&#x2013;<lpage>59</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10545-006-0384-7</pub-id>, PMID: <pub-id pub-id-type="pmid">17160617</pub-id></citation></ref>
<ref id="ref66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwasa</surname> <given-names>K.</given-names></name> <name><surname>Shima</surname> <given-names>K.</given-names></name> <name><surname>Komai</surname> <given-names>K.</given-names></name> <name><surname>Nishida</surname> <given-names>Y.</given-names></name> <name><surname>Yokota</surname> <given-names>T.</given-names></name> <name><surname>Yamada</surname> <given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Retinitis Pigmentosa and macular degeneration in a patient with ataxia with isolated vitamin e deficiency with a novel c.717 Del C mutation in the TTPA gene</article-title>. <source>J. Neurol. Sci.</source> <volume>345</volume>, <fpage>228</fpage>&#x2013;<lpage>230</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jns.2014.07.001</pub-id>, PMID: <pub-id pub-id-type="pmid">25066259</pub-id></citation></ref>
<ref id="ref67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname> <given-names>R.</given-names></name> <name><surname>Walters</surname> <given-names>S. P.</given-names></name> <name><surname>Al-Aswad</surname> <given-names>L. A.</given-names></name></person-group> (<year>2019</year>). <article-title>The current state of artificial intelligence in ophthalmology</article-title>. <source>Surv. Ophthalmol.</source> <volume>64</volume>, <fpage>233</fpage>&#x2013;<lpage>240</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.survophthal.2018.09.002</pub-id></citation></ref>
<ref id="ref68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kemp</surname> <given-names>K. C.</given-names></name> <name><surname>Cook</surname> <given-names>A. J.</given-names></name> <name><surname>Redondo</surname> <given-names>J.</given-names></name> <name><surname>Kurian</surname> <given-names>K. M.</given-names></name> <name><surname>Scolding</surname> <given-names>N. J.</given-names></name> <name><surname>Wilkins</surname> <given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Purkinje cell injury, structural plasticity and fusion in patients with Friedreich&#x2019;s ataxia</article-title>. <source>Acta Neuropathol. Commun.</source> <volume>4</volume>:<fpage>53</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40478-016-0326-3</pub-id>, PMID: <pub-id pub-id-type="pmid">27215193</pub-id></citation></ref>
<ref id="ref69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname> <given-names>A. O.</given-names></name> <name><surname>Aldahmesh</surname> <given-names>M. A.</given-names></name> <name><surname>Mohamed</surname> <given-names>J. Y.</given-names></name> <name><surname>Alkuraya</surname> <given-names>F. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Juvenile cataract morphology in 3 siblings not yet diagnosed with Cerebrotendinous Xanthomatosis</article-title>. <source>Ophthalmology</source> <volume>120</volume>, <fpage>956</fpage>&#x2013;<lpage>960</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ophtha.2012.10.032</pub-id>, PMID: <pub-id pub-id-type="pmid">23375591</pub-id></citation></ref>
<ref id="ref70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kipli</surname> <given-names>K.</given-names></name> <name><surname>Hoque</surname> <given-names>M. E.</given-names></name> <name><surname>Lim</surname> <given-names>L. T.</given-names></name> <name><surname>Mahmood</surname> <given-names>M. H.</given-names></name> <name><surname>Sahari</surname> <given-names>S. K.</given-names></name> <name><surname>Sapawi</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>A review on the extraction of quantitative retinal microvascular image feature</article-title>. <source>Comput. Math. Methods Med.</source> <volume>2018</volume>, <fpage>1</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2018/4019538</pub-id>, PMID: <pub-id pub-id-type="pmid">30065780</pub-id></citation></ref>
<ref id="ref71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klebe</surname> <given-names>S.</given-names></name> <name><surname>Depienne</surname> <given-names>C.</given-names></name> <name><surname>Gerber</surname> <given-names>S.</given-names></name> <name><surname>Challe</surname> <given-names>G.</given-names></name> <name><surname>Anheim</surname> <given-names>M.</given-names></name> <name><surname>Charles</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy</article-title>. <source>Brain</source> <volume>135</volume>, <fpage>2980</fpage>&#x2013;<lpage>2993</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/aws240</pub-id>, PMID: <pub-id pub-id-type="pmid">23065789</pub-id></citation></ref>
<ref id="ref72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname> <given-names>S.</given-names></name> <name><surname>Sekijima</surname> <given-names>Y.</given-names></name> <name><surname>Ogura</surname> <given-names>M.</given-names></name> <name><surname>Hori</surname> <given-names>M.</given-names></name> <name><surname>Matsuki</surname> <given-names>K.</given-names></name> <name><surname>Miida</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Cerebrotendinous Xanthomatosis: molecular pathogenesis, clinical Spectrum, diagnosis, and disease-modifying treatments</article-title>. <source>J. Atheroscler. Thromb.</source> <volume>28</volume>, <fpage>905</fpage>&#x2013;<lpage>925</lpage>. doi: <pub-id pub-id-type="doi">10.5551/jat.RV17055</pub-id>, PMID: <pub-id pub-id-type="pmid">33967188</pub-id></citation></ref>
<ref id="ref73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuriyama</surname> <given-names>M.</given-names></name> <name><surname>Fujiyama</surname> <given-names>J.</given-names></name> <name><surname>Yoshidome</surname> <given-names>H.</given-names></name> <name><surname>Takenaga</surname> <given-names>S.</given-names></name> <name><surname>Matsumuro</surname> <given-names>K.</given-names></name> <name><surname>Kasama</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>1991</year>). <article-title>Cerebrotendinous Xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature</article-title>. <source>J. Neurol. Sci.</source> <volume>102</volume>, <fpage>225</fpage>&#x2013;<lpage>232</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0022-510X(91)90073-G</pub-id>, PMID: <pub-id pub-id-type="pmid">2072121</pub-id></citation></ref>
<ref id="ref74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lax</surname> <given-names>N. Z.</given-names></name> <name><surname>Hepplewhite</surname> <given-names>P. D.</given-names></name> <name><surname>Reeve</surname> <given-names>A. K.</given-names></name> <name><surname>Nesbitt</surname> <given-names>V.</given-names></name> <name><surname>McFarland</surname> <given-names>R.</given-names></name> <name><surname>Jaros</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Cerebellar ataxia in patients with mitochondrial DNA disease</article-title>. <source>J. Neuropathol. Exp. Neurol.</source> <volume>71</volume>, <fpage>148</fpage>&#x2013;<lpage>161</lpage>. doi: <pub-id pub-id-type="doi">10.1097/NEN.0b013e318244477d</pub-id>, PMID: <pub-id pub-id-type="pmid">22249460</pub-id></citation></ref>
<ref id="ref75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Ber</surname> <given-names>I.</given-names></name> <name><surname>Moreira</surname> <given-names>M. C.</given-names></name> <name><surname>Rivaud-P&#x00E9;choux</surname> <given-names>S.</given-names></name> <name><surname>Chamayou</surname> <given-names>C.</given-names></name> <name><surname>Ochsner</surname> <given-names>F.</given-names></name> <name><surname>Kuntzer</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2003</year>). <article-title>Cerebellar ataxia with Oculomotor apraxia type 1: clinical and genetic studies</article-title>. <source>Brain</source> <volume>126</volume>, <fpage>2761</fpage>&#x2013;<lpage>2772</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awg283</pub-id></citation></ref>
<ref id="ref76"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Leigh</surname> <given-names>R. J.</given-names></name> <name><surname>Zee</surname> <given-names>D. S.</given-names></name></person-group> (<year>2015</year>). <source>The neurology of eye movements</source>. <publisher-loc>United Kingdom</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>.</citation></ref>
<ref id="ref77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname> <given-names>R. F.</given-names></name> <name><surname>Lederman</surname> <given-names>H. M.</given-names></name> <name><surname>Crawford</surname> <given-names>T. O.</given-names></name></person-group> (<year>1999</year>). <article-title>Ocular motor abnormalities in ataxia telangiectasia</article-title>. <source>Ann. Neurol.</source> <volume>46</volume>, <fpage>287</fpage>&#x2013;<lpage>295</lpage>. doi: <pub-id pub-id-type="doi">10.1002/1531-8249(199909)46:3&#x003C;287::AID-ANA3&#x003E;3.0.CO;2-0</pub-id>, PMID: <pub-id pub-id-type="pmid">10482258</pub-id></citation></ref>
<ref id="ref78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Fan</surname> <given-names>F.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Ning</surname> <given-names>L.</given-names></name> <name><surname>Lin</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Computer vision for brain disorders based primarily on ocular responses</article-title>. <source>Front. Neurol.</source> <volume>12</volume>:<fpage>4270</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2021.584270</pub-id></citation></ref>
<ref id="ref79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mariotti</surname> <given-names>C.</given-names></name> <name><surname>Gellera</surname> <given-names>C.</given-names></name> <name><surname>Rimoldi</surname> <given-names>M.</given-names></name> <name><surname>Mineri</surname> <given-names>R.</given-names></name> <name><surname>Uziel</surname> <given-names>G.</given-names></name> <name><surname>Zorzi</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families</article-title>. <source>Neurol. Sci.</source> <volume>25</volume>, <fpage>130</fpage>&#x2013;<lpage>137</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10072-004-0246-z</pub-id>, PMID: <pub-id pub-id-type="pmid">15300460</pub-id></citation></ref>
<ref id="ref80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martelli</surname> <given-names>A.</given-names></name> <name><surname>Puccio</surname> <given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation</article-title>. <source>Front Pharmacol</source> <volume>5</volume>:<fpage>130</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2014.00130</pub-id></citation></ref>
<ref id="ref81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinelli</surname> <given-names>P.</given-names></name> <name><surname>Rugarli</surname> <given-names>E. I.</given-names></name></person-group> (<year>2010</year>). <article-title>Emerging roles of mitochondrial proteases in Neurodegeneration</article-title>. <source>Biochim Biophys Acta</source> <volume>1797</volume>, <volume>1</volume>:<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbabio.2009.07.013</pub-id></citation></ref>
<ref id="ref82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maudoux</surname> <given-names>A.</given-names></name> <name><surname>Teissier</surname> <given-names>N.</given-names></name> <name><surname>Francois</surname> <given-names>M.</given-names></name> <name><surname>van den Abbeele</surname> <given-names>T.</given-names></name> <name><surname>Alberti</surname> <given-names>C.</given-names></name> <name><surname>Husson</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Vestibular impact of Friedreich ataxia in early onset patients</article-title>. <source>Cerebell Ataxias</source> <volume>7</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40673-020-00115-z</pub-id>, PMID: <pub-id pub-id-type="pmid">32514364</pub-id></citation></ref>
<ref id="ref83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname> <given-names>P.</given-names></name> <name><surname>Morgan</surname> <given-names>S. J.</given-names></name> <name><surname>Bosanquet</surname> <given-names>R. C.</given-names></name> <name><surname>Laker</surname> <given-names>M. F.</given-names></name></person-group> (<year>1990</year>). <article-title>A case of Cerebrotendinous Xanthomatosis II: the sterol content of a Cataractous lens</article-title>. <source>Br. J. Ophthalmol.</source> <volume>74</volume>, <fpage>629</fpage>&#x2013;<lpage>630</lpage>. doi: <pub-id pub-id-type="doi">10.1136/bjo.74.10.629</pub-id></citation></ref>
<ref id="ref84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mignarri</surname> <given-names>A.</given-names></name> <name><surname>Gallus</surname> <given-names>G. N.</given-names></name> <name><surname>Dotti</surname> <given-names>M. T.</given-names></name> <name><surname>Antonio</surname> <given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>A suspicion index for early diagnosis and treatment of Cerebrotendinous Xanthomatosis</article-title>. <source>J. Inherit. Metab. Dis.</source> <volume>37</volume>, <fpage>421</fpage>&#x2013;<lpage>429</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10545-013-9674-3</pub-id></citation></ref>
<ref id="ref85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milea</surname> <given-names>D.</given-names></name> <name><surname>Najjar</surname> <given-names>R. P.</given-names></name> <name><surname>Zhubo</surname> <given-names>J.</given-names></name> <name><surname>Ting</surname> <given-names>D.</given-names></name> <name><surname>Vasseneix</surname> <given-names>C.</given-names></name> <name><surname>Xu</surname> <given-names>X.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Artificial intelligence to detect papilledema from ocular fundus photographs</article-title>. <source>N. Engl. J. Med.</source> <volume>382</volume>, <fpage>1687</fpage>&#x2013;<lpage>1695</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1917130</pub-id>, PMID: <pub-id pub-id-type="pmid">32286748</pub-id></citation></ref>
<ref id="ref86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minakaran</surname> <given-names>N.</given-names></name> <name><surname>de Carvalho</surname> <given-names>E. R.</given-names></name> <name><surname>Petzold</surname> <given-names>A.</given-names></name> <name><surname>Wong</surname> <given-names>S. H.</given-names></name></person-group> (<year>2021</year>). <article-title>Optical coherence tomography (OCT) in Neuro-ophthalmology</article-title>. <source>Eye</source> <volume>35</volume>, <fpage>17</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41433-020-01288-x</pub-id></citation></ref>
<ref id="ref87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minnerop</surname> <given-names>M.</given-names></name> <name><surname>Kurzwelly</surname> <given-names>D.</given-names></name> <name><surname>Wagner</surname> <given-names>H.</given-names></name> <name><surname>Soehn</surname> <given-names>A. S.</given-names></name> <name><surname>Reichbauer</surname> <given-names>J.</given-names></name> <name><surname>Tao</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia</article-title>. <source>Brain</source> <volume>140</volume>, <fpage>1561</fpage>&#x2013;<lpage>1578</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awx095</pub-id>, PMID: <pub-id pub-id-type="pmid">28459997</pub-id></citation></ref>
<ref id="ref88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morani</surname> <given-names>F.</given-names></name> <name><surname>Doccini</surname> <given-names>S.</given-names></name> <name><surname>Sirica</surname> <given-names>R.</given-names></name> <name><surname>Paterno</surname> <given-names>M.</given-names></name> <name><surname>Pezzini</surname> <given-names>F.</given-names></name> <name><surname>Ricca</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Functional Transcriptome analysis in ARSACS KO cell model reveals a role of Sacsin in autophagy</article-title>. <source>Sci. Rep.</source> <volume>9</volume>:<fpage>11878</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-019-48047-x</pub-id>, PMID: <pub-id pub-id-type="pmid">31417125</pub-id></citation></ref>
<ref id="ref89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname> <given-names>M.-C.</given-names></name> <name><surname>Klur</surname> <given-names>S.</given-names></name> <name><surname>Watanabe</surname> <given-names>M.</given-names></name> <name><surname>N&#x00E9;meth</surname> <given-names>A. H.</given-names></name> <name><surname>Ber</surname> <given-names>I. L.</given-names></name> <name><surname>Moniz</surname> <given-names>J.-C.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Senataxin, the Ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2</article-title>. <source>Nat. Genet.</source> <volume>36</volume>, <fpage>225</fpage>&#x2013;<lpage>227</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng1303</pub-id>, PMID: <pub-id pub-id-type="pmid">14770181</pub-id></citation></ref>
<ref id="ref90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname> <given-names>S. J.</given-names></name> <name><surname>McKenna</surname> <given-names>P.</given-names></name> <name><surname>Bosanquet</surname> <given-names>R. C.</given-names></name></person-group> (<year>1989</year>). <article-title>Case of Cerebrotendinous Xanthomatosis. I: unusual ophthalmic features</article-title>. <source>Br. J. Ophthalmol.</source> <volume>73</volume>, <fpage>1011</fpage>&#x2013;<lpage>1014</lpage>.</citation></ref>
<ref id="ref91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naess</surname> <given-names>K.</given-names></name> <name><surname>Barbaro</surname> <given-names>M.</given-names></name> <name><surname>Bruhn</surname> <given-names>H.</given-names></name> <name><surname>Wibom</surname> <given-names>R.</given-names></name> <name><surname>Nennesmo</surname> <given-names>I.</given-names></name> <name><surname>von D&#x00F6;beln</surname> <given-names>U.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Complete deletion of a POLG1 allele in a patient with Alpers syndrome</article-title>. <source>JIMD Rep</source> <volume>4</volume>, <fpage>67</fpage>&#x2013;<lpage>73</lpage>. doi: <pub-id pub-id-type="doi">10.1007/8904_2011_73</pub-id></citation></ref>
<ref id="ref92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naureckiene</surname> <given-names>S.</given-names></name> <name><surname>Sleat</surname> <given-names>D. E.</given-names></name> <name><surname>Lackland</surname> <given-names>H.</given-names></name> <name><surname>Fensom</surname> <given-names>A.</given-names></name> <name><surname>Vanier</surname> <given-names>M. T.</given-names></name> <name><surname>Wattiaux</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2000</year>). <article-title>Identification of HE1 as the second gene of Niemann-pick C disease</article-title>. <source>Science</source> <volume>290</volume>, <fpage>2298</fpage>&#x2013;<lpage>2301</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.290.5500.2298</pub-id>, PMID: <pub-id pub-id-type="pmid">11125141</pub-id></citation></ref>
<ref id="ref93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>N. J.</given-names></name> <name><surname>Yu-Wai-Man</surname> <given-names>P.</given-names></name> <name><surname>Biousse</surname> <given-names>V.</given-names></name> <name><surname>Carelli</surname> <given-names>V.</given-names></name></person-group> (<year>2023</year>). <article-title>Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management</article-title>. <source>Lancet Neurol</source> <volume>22</volume>, <fpage>172</fpage>&#x2013;<lpage>188</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(22)00174-0</pub-id></citation></ref>
<ref id="ref94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noval</surname> <given-names>S.</given-names></name> <name><surname>Contreras</surname> <given-names>I.</given-names></name> <name><surname>Sanz-Gallego</surname> <given-names>I.</given-names></name> <name><surname>Manrique</surname> <given-names>R. K.</given-names></name> <name><surname>Arpa</surname> <given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Ophthalmic features of Friedreich ataxia</article-title>. <source>Eye</source> <volume>26</volume>, <fpage>315</fpage>&#x2013;<lpage>320</lpage>. doi: <pub-id pub-id-type="doi">10.1038/eye.2011.291</pub-id>, PMID: <pub-id pub-id-type="pmid">22094302</pub-id></citation></ref>
<ref id="ref95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmeri</surname> <given-names>S.</given-names></name> <name><surname>Rufa</surname> <given-names>A.</given-names></name> <name><surname>Pucci</surname> <given-names>B.</given-names></name> <name><surname>Santarnecchi</surname> <given-names>E.</given-names></name> <name><surname>Malandrini</surname> <given-names>A.</given-names></name> <name><surname>Stromillo</surname> <given-names>M. L.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Clinical course of two Italian siblings with ataxia-telangiectasia-like disorder</article-title>. <source>Cerebellum</source> <volume>12</volume>, <fpage>596</fpage>&#x2013;<lpage>599</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-013-0460-4</pub-id>, PMID: <pub-id pub-id-type="pmid">23436002</pub-id></citation></ref>
<ref id="ref96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panwar</surname> <given-names>N.</given-names></name> <name><surname>Huang</surname> <given-names>P.</given-names></name> <name><surname>Lee</surname> <given-names>J.</given-names></name> <name><surname>Keane</surname> <given-names>P. A.</given-names></name> <name><surname>Chuan</surname> <given-names>T. S.</given-names></name> <name><surname>Richhariya</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Fundus photography in the 21st century-a review of recent technological advances and their implications for worldwide healthcare</article-title>. <source>Telemed e-Health</source> <volume>22</volume>, <fpage>198</fpage>&#x2013;<lpage>208</lpage>. doi: <pub-id pub-id-type="doi">10.1089/tmj.2015.0068</pub-id>, PMID: <pub-id pub-id-type="pmid">26308281</pub-id></citation></ref>
<ref id="ref97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parkinson</surname> <given-names>M. H.</given-names></name> <name><surname>Bartmann</surname> <given-names>A. P.</given-names></name> <name><surname>Clayton</surname> <given-names>L. M. S.</given-names></name> <name><surname>Nethisinghe</surname> <given-names>S.</given-names></name> <name><surname>Pfundt</surname> <given-names>R.</given-names></name> <name><surname>Chapple</surname> <given-names>J. P.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay</article-title>. <source>Brain</source> <volume>141</volume>, <fpage>989</fpage>&#x2013;<lpage>999</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awy028</pub-id>, PMID: <pub-id pub-id-type="pmid">29538656</pub-id></citation></ref>
<ref id="ref98"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Patterson</surname> <given-names>M.</given-names></name></person-group> (<year>2020</year>). &#x201C;<article-title>Niemann-pick disease type C</article-title>&#x201D; in <source>GeneReviews&#x00AE;</source>. eds. <person-group person-group-type="editor"><name><surname>Adam</surname> <given-names>M. P.</given-names></name> <name><surname>Feldman</surname> <given-names>J.</given-names></name> <name><surname>Mirzaa</surname> <given-names>G. M.</given-names></name> <etal/></person-group>. (<publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington</publisher-name>)</citation></ref>
<ref id="ref99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patterson</surname> <given-names>M. C.</given-names></name> <name><surname>Clayton</surname> <given-names>P.</given-names></name> <name><surname>Gissen</surname> <given-names>P.</given-names></name> <name><surname>Anheim</surname> <given-names>M.</given-names></name> <name><surname>Bauer</surname> <given-names>P.</given-names></name> <name><surname>Bonnot</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Recommendations for the detection and diagnosis of Niemann-pick disease type C</article-title>. <source>Neurology</source> <volume>7</volume>, <fpage>499</fpage>&#x2013;<lpage>511</lpage>. doi: <pub-id pub-id-type="doi">10.1212/CPJ.0000000000000399</pub-id></citation></ref>
<ref id="ref100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname> <given-names>G.</given-names></name> <name><surname>Gorman</surname> <given-names>G. S.</given-names></name> <name><surname>Griffin</surname> <given-names>H.</given-names></name> <name><surname>Kurzawa-Akanbi</surname> <given-names>M.</given-names></name> <name><surname>Blakely</surname> <given-names>E. L.</given-names></name> <name><surname>Wilson</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Mutations in the SPG7 gene cause chronic progressive external Ophthalmoplegia through disordered mitochondrial DNA maintenance</article-title>. <source>Brain</source> <volume>137</volume>, <fpage>1323</fpage>&#x2013;<lpage>1336</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awu060</pub-id>, PMID: <pub-id pub-id-type="pmid">24727571</pub-id></citation></ref>
<ref id="ref101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pujari</surname> <given-names>A.</given-names></name> <name><surname>Bhaskaran</surname> <given-names>K.</given-names></name> <name><surname>Sharma</surname> <given-names>P.</given-names></name> <name><surname>Singh</surname> <given-names>P.</given-names></name> <name><surname>Phuljhele</surname> <given-names>S.</given-names></name> <name><surname>Saxena</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Optical coherence tomography angiography in Neuro-ophthalmology: current clinical role and future perspectives</article-title>. <source>Surv. Ophthalmol.</source> <volume>66</volume>, <fpage>471</fpage>&#x2013;<lpage>481</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.survophthal.2020.10.009</pub-id>, PMID: <pub-id pub-id-type="pmid">33157113</pub-id></citation></ref>
<ref id="ref102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>S.</given-names></name> <name><surname>Copeland</surname> <given-names>W. C.</given-names></name></person-group> (<year>2019</year>). <article-title>POLG-related disorders and their neurological manifestations</article-title>. <source>Nat. Rev. Neurol.</source> <volume>15</volume>, <fpage>40</fpage>&#x2013;<lpage>52</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41582-018-0101-0</pub-id></citation></ref>
<ref id="ref103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajalakshmi</surname> <given-names>R.</given-names></name> <name><surname>Prathiba</surname> <given-names>V.</given-names></name> <name><surname>Arulmalar</surname> <given-names>S.</given-names></name> <name><surname>Usha</surname> <given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Review of retinal cameras for global coverage of diabetic retinopathy screening</article-title>. <source>Eye</source> <volume>35</volume>, <fpage>162</fpage>&#x2013;<lpage>172</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41433-020-01262-7</pub-id></citation></ref>
<ref id="ref104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rezende Filho</surname> <given-names>F. M.</given-names></name> <name><surname>Bremner</surname> <given-names>F.</given-names></name> <name><surname>Pedroso</surname> <given-names>J. L.</given-names></name> <name><surname>de Andrade</surname> <given-names>J. B. C.</given-names></name> <name><surname>Marianelli</surname> <given-names>B. F.</given-names></name> <name><surname>Louren&#x00E7;o</surname> <given-names>C. M.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Retinal architecture in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): insights into disease pathogenesis and biomarkers</article-title>. <source>Mov. Disord.</source> <volume>36</volume>, <fpage>2027</fpage>&#x2013;<lpage>2035</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.28612</pub-id></citation></ref>
<ref id="ref105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname> <given-names>P.</given-names></name> <name><surname>Rosonina</surname> <given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Regulating autophagy: a novel role for SETX (Senataxin)</article-title>. <source>Neural Regen. Res.</source> <volume>16</volume>, <fpage>2008</fpage>&#x2013;<lpage>2009</lpage>. doi: <pub-id pub-id-type="doi">10.4103/1673-5374.308091</pub-id></citation></ref>
<ref id="ref106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname> <given-names>P.</given-names></name> <name><surname>de Hoz</surname> <given-names>R.</given-names></name> <name><surname>Cadena</surname> <given-names>M.</given-names></name> <name><surname>Salobrar-Garc&#x00ED;a</surname> <given-names>E.</given-names></name> <name><surname>Fern&#x00E1;ndez-Albarral</surname> <given-names>J. A.</given-names></name> <name><surname>L&#x00F3;pez-Cuenca</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Neuro-ophthalmological findings in Friedreich&#x2019;s ataxia</article-title>. <source>J Personal Med</source> <volume>11</volume>:<fpage>708</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jpm11080708</pub-id>, PMID: <pub-id pub-id-type="pmid">34442352</pub-id></citation></ref>
<ref id="ref107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname> <given-names>L. E. L.</given-names></name> <name><surname>Aw</surname> <given-names>W. Y.</given-names></name> <name><surname>Hixson</surname> <given-names>K. M.</given-names></name> <name><surname>Novoselova</surname> <given-names>T. V.</given-names></name> <name><surname>Havener</surname> <given-names>T. M.</given-names></name> <name><surname>Howell</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Multi-Omic profiling reveals the ataxia protein Sacsin is required for integrin trafficking and synaptic organization</article-title>. <source>Cell Rep.</source> <volume>41</volume>:<fpage>111580</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2022.111580</pub-id>, PMID: <pub-id pub-id-type="pmid">36323248</pub-id></citation></ref>
<ref id="ref108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ronsin</surname> <given-names>S.</given-names></name> <name><surname>Hannoun</surname> <given-names>S.</given-names></name> <name><surname>Thobois</surname> <given-names>S.</given-names></name> <name><surname>Petiot</surname> <given-names>P.</given-names></name> <name><surname>Vighetto</surname> <given-names>A.</given-names></name> <name><surname>Cotton</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>A new MRI marker of ataxia with Oculomotor apraxia</article-title>. <source>Eur. J. Radiol.</source> <volume>110</volume>, <fpage>187</fpage>&#x2013;<lpage>192</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejrad.2018.11.035</pub-id>, PMID: <pub-id pub-id-type="pmid">30599859</pub-id></citation></ref>
<ref id="ref109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosini</surname> <given-names>F.</given-names></name> <name><surname>Pretegiani</surname> <given-names>E.</given-names></name> <name><surname>Mignarri</surname> <given-names>A.</given-names></name> <name><surname>Optican</surname> <given-names>L. M.</given-names></name> <name><surname>Serchi</surname> <given-names>V.</given-names></name> <name><surname>de Stefano</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>The role of dentate nuclei in human Oculomotor control: insights from Cerebrotendinous Xanthomatosis</article-title>. <source>J. Physiol.</source> <volume>595</volume>, <fpage>3607</fpage>&#x2013;<lpage>3620</lpage>. doi: <pub-id pub-id-type="doi">10.1113/JP273670</pub-id>, PMID: <pub-id pub-id-type="pmid">28168705</pub-id></citation></ref>
<ref id="ref110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname> <given-names>M.</given-names></name> <name><surname>Anheim</surname> <given-names>M.</given-names></name> <name><surname>Durr</surname> <given-names>A.</given-names></name> <name><surname>Klein</surname> <given-names>C.</given-names></name> <name><surname>Koenig</surname> <given-names>M.</given-names></name> <name><surname>Synofzik</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>The genetic nomenclature of recessive cerebellar ataxias</article-title>. <source>Mov. Disord.</source> <volume>33</volume>, <fpage>1056</fpage>&#x2013;<lpage>1076</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.27415</pub-id>, PMID: <pub-id pub-id-type="pmid">29756227</pub-id></citation></ref>
<ref id="ref111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rouzier</surname> <given-names>C.</given-names></name> <name><surname>Chaussenot</surname> <given-names>A.</given-names></name> <name><surname>Serre</surname> <given-names>V.</given-names></name> <name><surname>Fragaki</surname> <given-names>K.</given-names></name> <name><surname>Bannwarth</surname> <given-names>S.</given-names></name> <name><surname>Ait-el-Mkadem</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Quantitative multiplex PCR of short fluorescent fragments for the detection of large intragenic POLG rearrangements in a large French cohort</article-title>. <source>Eur. J. Hum. Genet.</source> <volume>22</volume>, <fpage>542</fpage>&#x2013;<lpage>550</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ejhg.2013.171</pub-id>, PMID: <pub-id pub-id-type="pmid">23921535</pub-id></citation></ref>
<ref id="ref112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Safdar</surname> <given-names>A.</given-names></name> <name><surname>Annis</surname> <given-names>S.</given-names></name> <name><surname>Kraytsberg</surname> <given-names>Y.</given-names></name> <name><surname>Laverack</surname> <given-names>C.</given-names></name> <name><surname>Saleem</surname> <given-names>A.</given-names></name> <name><surname>Popadin</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Amelioration of premature aging in MtDNA Mutator mouse by exercise: the interplay of oxidative stress, PGC-1&#x03B1;, P53, and DNA damage. A hypothesis</article-title>. <source>Curr. Opin. Genet. Dev.</source> <volume>38</volume>, <fpage>127</fpage>&#x2013;<lpage>132</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.gde.2016.06.011</pub-id>, PMID: <pub-id pub-id-type="pmid">27497229</pub-id></citation></ref>
<ref id="ref113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname> <given-names>I. H.</given-names></name> <name><surname>Beaudin</surname> <given-names>M.</given-names></name> <name><surname>Klein</surname> <given-names>C. J.</given-names></name> <name><surname>Dupr&#x00E9;</surname> <given-names>N.</given-names></name></person-group> (<year>2023</year>). <article-title>Treatment and Management of Autosomal Recessive Cerebellar Ataxias: current advances and future perspectives</article-title>. <source>CNS Neurol Disord Drug Targets</source> <volume>22</volume>, <fpage>678</fpage>&#x2013;<lpage>697</lpage>. doi: <pub-id pub-id-type="doi">10.2174/1871527321666220418114846</pub-id></citation></ref>
<ref id="ref114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salen</surname> <given-names>G.</given-names></name></person-group> (<year>1971</year>). <article-title>Cholestanol deposition in Cerebrotendinous Xanthomatosis. A possible mechanism</article-title>. <source>Ann. Intern. Med.</source> <volume>75</volume>, <fpage>843</fpage>&#x2013;<lpage>851</lpage>. doi: <pub-id pub-id-type="doi">10.7326/0003-4819-75-6-843</pub-id></citation></ref>
<ref id="ref115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salen</surname> <given-names>G.</given-names></name> <name><surname>Steiner</surname> <given-names>R. D.</given-names></name></person-group> (<year>2017</year>). <article-title>Epidemiology, diagnosis, and treatment of Cerebrotendinous Xanthomatosis (CTX)</article-title>. <source>J. Inherit. Metab. Dis.</source> <volume>40</volume>, <fpage>771</fpage>&#x2013;<lpage>781</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10545-017-0093-8</pub-id></citation></ref>
<ref id="ref116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salviati</surname> <given-names>L.</given-names></name> <name><surname>Trevisson</surname> <given-names>E.</given-names></name> <name><surname>Rodriguez Hernandez</surname> <given-names>M. A.</given-names></name> <name><surname>Casarin</surname> <given-names>A.</given-names></name> <name><surname>Pertegato</surname> <given-names>V.</given-names></name> <name><surname>Doimo</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency</article-title>. <source>J. Med. Genet.</source> <volume>49</volume>, <fpage>187</fpage>&#x2013;<lpage>191</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jmedgenet-2011-100394</pub-id>, PMID: <pub-id pub-id-type="pmid">22368301</pub-id></citation></ref>
<ref id="ref117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x00E1;nchez-Ferrero</surname> <given-names>E.</given-names></name> <name><surname>Coto</surname> <given-names>E.</given-names></name> <name><surname>Beetz</surname> <given-names>C.</given-names></name> <name><surname>G&#x00E1;mez</surname> <given-names>J.</given-names></name> <name><surname>Corao</surname> <given-names>A. I.</given-names></name> <name><surname>D&#x00ED;az</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V</article-title>. <source>Clin. Genet.</source> <volume>83</volume>, <fpage>257</fpage>&#x2013;<lpage>262</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1399-0004.2012.01896.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22571692</pub-id></citation></ref>
<ref id="ref118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Satya-Murti</surname> <given-names>S.</given-names></name> <name><surname>Howard</surname> <given-names>L.</given-names></name> <name><surname>Krohel</surname> <given-names>G.</given-names></name> <name><surname>Wolf</surname> <given-names>B.</given-names></name></person-group> (<year>1986</year>). <article-title>The Spectrum of neurologic disorder from vitamin E deficiency</article-title>. <source>Neurology</source> <volume>36</volume>, <fpage>917</fpage>&#x2013;<lpage>921</lpage>. doi: <pub-id pub-id-type="doi">10.1212/wnl.36.7.917</pub-id></citation></ref>
<ref id="ref119"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Schuelke</surname> <given-names>M.</given-names></name></person-group> (<year>2023</year>). &#x201C;<article-title>Ataxia with vitamin E deficiency</article-title>&#x201D; in <source>GeneReviews&#x00AE;</source>. eds. <person-group person-group-type="editor"><name><surname>Adam</surname> <given-names>M. P.</given-names></name> <etal/></person-group>. (<publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington</publisher-name>)</citation></ref>
<ref id="ref120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seyer</surname> <given-names>L. A.</given-names></name> <name><surname>Galetta</surname> <given-names>K.</given-names></name> <name><surname>Wilson</surname> <given-names>J.</given-names></name> <name><surname>Sakai</surname> <given-names>R.</given-names></name> <name><surname>Perlman</surname> <given-names>S.</given-names></name> <name><surname>Mathews</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Analysis of the visual system in Friedreich ataxia</article-title>. <source>J. Neurol.</source> <volume>260</volume>, <fpage>2362</fpage>&#x2013;<lpage>2369</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-013-6978-z</pub-id>, PMID: <pub-id pub-id-type="pmid">23775342</pub-id></citation></ref>
<ref id="ref121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname> <given-names>A. G.</given-names></name> <name><surname>Marti</surname> <given-names>S.</given-names></name> <name><surname>Tarnutzer</surname> <given-names>A. A.</given-names></name> <name><surname>Palla</surname> <given-names>A.</given-names></name> <name><surname>Crawford</surname> <given-names>T. O.</given-names></name> <name><surname>Straumann</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Ataxia telangiectasia: a &#x2018;disease model&#x2019; to understand the cerebellar control of vestibular reflexes</article-title>. <source>J. Neurophysiol.</source> <volume>105</volume>, <fpage>3034</fpage>&#x2013;<lpage>3041</lpage>. doi: <pub-id pub-id-type="doi">10.1152/jn.00721.2010</pub-id>, PMID: <pub-id pub-id-type="pmid">21471399</pub-id></citation></ref>
<ref id="ref122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaikh</surname> <given-names>A. G.</given-names></name> <name><surname>Marti</surname> <given-names>S.</given-names></name> <name><surname>Tarnutzer</surname> <given-names>A. A.</given-names></name> <name><surname>Palla</surname> <given-names>A.</given-names></name> <name><surname>Crawford</surname> <given-names>T. O.</given-names></name> <name><surname>Straumann</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Gaze fixation deficits and their implication in ataxia-telangiectasia</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source> <volume>80</volume>, <fpage>858</fpage>&#x2013;<lpage>864</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.2008.170522</pub-id>, PMID: <pub-id pub-id-type="pmid">19357126</pub-id></citation></ref>
<ref id="ref123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stelten</surname> <given-names>B. M. L.</given-names></name> <name><surname>Huidekoper</surname> <given-names>H. H.</given-names></name> <name><surname>van de Warrenburg</surname> <given-names>B. P. C.</given-names></name> <name><surname>Brilstra</surname> <given-names>E. H.</given-names></name> <name><surname>Hollak</surname> <given-names>C. E. M.</given-names></name> <name><surname>Haak</surname> <given-names>H. R.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Long-term treatment effect in Cerebrotendinous Xanthomatosis depends on age at treatment start</article-title>. <source>Neurology</source> <volume>92</volume>, <fpage>e83</fpage>&#x2013;<lpage>e95</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000006731</pub-id>, PMID: <pub-id pub-id-type="pmid">30530799</pub-id></citation></ref>
<ref id="ref124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname> <given-names>J. C.</given-names></name> <name><surname>Murphy</surname> <given-names>S. M.</given-names></name> <name><surname>Davagnanam</surname> <given-names>I.</given-names></name> <name><surname>Phadke</surname> <given-names>R.</given-names></name> <name><surname>Anderson</surname> <given-names>G.</given-names></name> <name><surname>Nethisinghe</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>The ARSACS phenotype can include Supranuclear gaze palsy and skin Lipofuscin deposits</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source> <volume>84</volume>, <fpage>114</fpage>&#x2013;<lpage>116</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2012-303634</pub-id>, PMID: <pub-id pub-id-type="pmid">23123642</pub-id></citation></ref>
<ref id="ref125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname> <given-names>G. S.</given-names></name> <name><surname>Maser</surname> <given-names>R. S.</given-names></name> <name><surname>Stankovic</surname> <given-names>T.</given-names></name> <name><surname>Bressan</surname> <given-names>D. A.</given-names></name> <name><surname>Kaplan</surname> <given-names>M. I.</given-names></name> <name><surname>Jaspers</surname> <given-names>N. G. J.</given-names></name> <etal/></person-group>. (<year>1999</year>). <article-title>The DNA double-Strand break repair gene HMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder</article-title>. <source>Cell</source> <volume>99</volume>, <fpage>577</fpage>&#x2013;<lpage>587</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81547-0</pub-id>, PMID: <pub-id pub-id-type="pmid">10612394</pub-id></citation></ref>
<ref id="ref126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoean</surname> <given-names>C.</given-names></name> <name><surname>Stoean</surname> <given-names>R.</given-names></name> <name><surname>Atencia</surname> <given-names>M.</given-names></name> <name><surname>Abdar</surname> <given-names>M.</given-names></name> <name><surname>Vel&#x00E1;zquez-P&#x00E9;rez</surname> <given-names>L.</given-names></name> <name><surname>Khosravi</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Automated detection of Presymptomatic conditions in Spinocerebellar ataxia type 2 using Monte Carlo dropout and deep neural network techniques with Electrooculogram signals</article-title>. <source>Sensor</source> <volume>20</volume>:<fpage>3032</fpage>. doi: <pub-id pub-id-type="doi">10.3390/s20113032</pub-id>, PMID: <pub-id pub-id-type="pmid">32471077</pub-id></citation></ref>
<ref id="ref127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Synofzik</surname> <given-names>M.</given-names></name> <name><surname>H&#x00E9;l&#x00E8;ne</surname> <given-names>P.</given-names></name> <name><surname>Fanny</surname> <given-names>M.</given-names></name> <name><surname>Ludger</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Autosomal recessive cerebellar ataxias: paving the way toward targeted molecular therapies</article-title>. <source>Neuron</source> <volume>101</volume>, <fpage>560</fpage>&#x2013;<lpage>583</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuron.2019.01.049</pub-id></citation></ref>
<ref id="ref128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Synofzik</surname> <given-names>M.</given-names></name> <name><surname>Sch&#x00FC;le</surname> <given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Overcoming the divide between ataxias and spastic paraplegias: shared phenotypes, genes, and pathways</article-title>. <source>Mov. Disord.</source> <volume>32</volume>, <fpage>332</fpage>&#x2013;<lpage>345</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.26944</pub-id></citation></ref>
<ref id="ref129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Synofzik</surname> <given-names>M.</given-names></name> <name><surname>Soehn</surname> <given-names>A. S.</given-names></name> <name><surname>Gburek-Augustat</surname> <given-names>J.</given-names></name> <name><surname>Schicks</surname> <given-names>J.</given-names></name> <name><surname>Karle</surname> <given-names>K. N.</given-names></name> <name><surname>Sch&#x00FC;le</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging Spectrum</article-title>. <source>Orphanet J. Rare Dis.</source> <volume>8</volume>:<fpage>41</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1750-1172-8-41</pub-id>, PMID: <pub-id pub-id-type="pmid">23497566</pub-id></citation></ref>
<ref id="ref130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Synofzik</surname> <given-names>M.</given-names></name> <name><surname>Srulijes</surname> <given-names>K.</given-names></name> <name><surname>Godau</surname> <given-names>J.</given-names></name> <name><surname>Berg</surname> <given-names>D.</given-names></name> <name><surname>Sch&#x00F6;ls</surname> <given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>Characterizing POLG ataxia: clinics, electrophysiology and imaging</article-title>. <source>Cerebellum</source> <volume>11</volume>, <fpage>1002</fpage>&#x2013;<lpage>1011</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-012-0378-2</pub-id>, PMID: <pub-id pub-id-type="pmid">22528963</pub-id></citation></ref>
<ref id="ref131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szmulewicz</surname> <given-names>D. J.</given-names></name> <name><surname>Roberts</surname> <given-names>L.</given-names></name> <name><surname>McLean</surname> <given-names>C. A.</given-names></name> <name><surname>MacDougall</surname> <given-names>H. G.</given-names></name> <name><surname>Halmagyi</surname> <given-names>G. M.</given-names></name> <name><surname>Storey</surname> <given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Proposed diagnostic Criteria for cerebellar ataxia with neuropathy and vestibular Areflexia syndrome (CANVAS)</article-title>. <source>Neurology</source> <volume>6</volume>, <fpage>61</fpage>&#x2013;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1212/CPJ.0000000000000215</pub-id>, PMID: <pub-id pub-id-type="pmid">26918204</pub-id></citation></ref>
<ref id="ref132"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>S. Y.</given-names></name> <name><surname>Shaikh</surname> <given-names>A. G.</given-names></name></person-group> (<year>2019</year>). <article-title>Past and present of eye movement abnormalities in ataxia-telangiectasia</article-title>. <source>Cerebellum</source> <volume>18</volume>, <fpage>556</fpage>&#x2013;<lpage>564</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-018-0990-x</pub-id></citation></ref>
<ref id="ref133"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terryn</surname> <given-names>J.</given-names></name> <name><surname>Van Eesbeeck</surname> <given-names>A.</given-names></name> <name><surname>Vermeer</surname> <given-names>S.</given-names></name> <name><surname>Vandenberghe</surname> <given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>The characteristic eye movement disorder of RFC1-linked CANVAS</article-title>. <source>Move Disord Clin Pract</source> <volume>7</volume>, <fpage>230</fpage>&#x2013;<lpage>231</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mdc3.12896</pub-id></citation></ref>
<ref id="ref134"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname> <given-names>D. R.</given-names></name> <name><surname>Z&#x00FC;chner</surname> <given-names>S.</given-names></name> <name><surname>Gierer</surname> <given-names>S.</given-names></name> <name><surname>Schulte</surname> <given-names>C.</given-names></name> <name><surname>Sch&#x00F6;ls</surname> <given-names>L.</given-names></name> <name><surname>Sch&#x00FC;le</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Abnormal Paraplegin expression in swollen Neurites, &#x03C4;-and &#x03B1;-Synuclein pathology in a case of hereditary spastic paraplegia SPG7 with an Ala510Val mutation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>16</volume>, <fpage>25050</fpage>&#x2013;<lpage>25066</lpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms161025050</pub-id>, PMID: <pub-id pub-id-type="pmid">26506339</pub-id></citation></ref>
<ref id="ref135"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas-Black</surname> <given-names>G.</given-names></name> <name><surname>Altmann</surname> <given-names>D. R.</given-names></name> <name><surname>Crook</surname> <given-names>H.</given-names></name> <name><surname>Solanky</surname> <given-names>N.</given-names></name> <name><surname>Carrasco</surname> <given-names>F. P.</given-names></name> <name><surname>Battiston</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Multimodal analysis of the visual pathways in Friedreich&#x2019;s ataxia reveals novel biomarkers</article-title>. <source>Mov. Disord.</source> <volume>38</volume>, <fpage>959</fpage>&#x2013;<lpage>969</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.29277</pub-id>, PMID: <pub-id pub-id-type="pmid">36433650</pub-id></citation></ref>
<ref id="ref136"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tibrewal</surname> <given-names>S.</given-names></name> <name><surname>Barton Duell</surname> <given-names>P.</given-names></name> <name><surname>DeBarber</surname> <given-names>A. E.</given-names></name> <name><surname>Loh</surname> <given-names>A. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Cerebrotendinous Xanthomatosis: early diagnosis on the basis of juvenile cataracts</article-title>. <source>J. AAPOS</source> <volume>21</volume>, <fpage>505</fpage>&#x2013;<lpage>507</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaapos.2017.07.211</pub-id></citation></ref>
<ref id="ref137"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tilikete</surname> <given-names>C.</given-names></name> <name><surname>Virginie</surname> <given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Hypertrophic Olivary degeneration and palatal or Oculopalatal tremor</article-title>. <source>Front. Neurol.</source> <volume>8</volume>:<fpage>302</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fneur.2017.00302</pub-id></citation></ref>
<ref id="ref138"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trasch&#x00FC;tz</surname> <given-names>A.</given-names></name> <name><surname>Cortese</surname> <given-names>A.</given-names></name> <name><surname>Reich</surname> <given-names>S.</given-names></name> <name><surname>Dominik</surname> <given-names>N.</given-names></name> <name><surname>Faber</surname> <given-names>J.</given-names></name> <name><surname>Jacobi</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Natural history, phenotypic Spectrum, and discriminative features of multisystemic RFC1 disease</article-title>. <source>Neurology</source> <volume>96</volume>, <fpage>e1369</fpage>&#x2013;<lpage>e1382</lpage>. doi: <pub-id pub-id-type="doi">10.1212/WNL.0000000000011528</pub-id>, PMID: <pub-id pub-id-type="pmid">33495376</pub-id></citation></ref>
<ref id="ref139"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trasch&#x00FC;tz</surname> <given-names>A.</given-names></name> <name><surname>Schirinzi</surname> <given-names>T.</given-names></name> <name><surname>Laugwitz</surname> <given-names>L.</given-names></name> <name><surname>Murray</surname> <given-names>N. H.</given-names></name> <name><surname>Bingman</surname> <given-names>C. A.</given-names></name> <name><surname>Reich</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Clinico-genetic, imaging and molecular delineation of COQ8A-ataxia: a multicenter study of 59 patients</article-title>. <source>Ann. Neurol.</source> <volume>88</volume>, <fpage>251</fpage>&#x2013;<lpage>263</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.25751</pub-id>, PMID: <pub-id pub-id-type="pmid">32337771</pub-id></citation></ref>
<ref id="ref140"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tulli</surname> <given-names>S.</given-names></name> <name><surname>del Bondio</surname> <given-names>A.</given-names></name> <name><surname>Baderna</surname> <given-names>V.</given-names></name> <name><surname>Mazza</surname> <given-names>D.</given-names></name> <name><surname>Codazzi</surname> <given-names>F.</given-names></name> <name><surname>Pierson</surname> <given-names>T. M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Pathogenic variants in the AFG3L2 Proteolytic domain cause SCA28 through Haploinsufficiency and Proteostatic stress-driven OMA1 activation</article-title>. <source>J. Med. Genet.</source> <volume>56</volume>, <fpage>499</fpage>&#x2013;<lpage>511</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jmedgenet-2018-105766</pub-id>, PMID: <pub-id pub-id-type="pmid">30910913</pub-id></citation></ref>
<ref id="ref141"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Van Bogaert</surname> <given-names>L.</given-names></name> <name><surname>Scherer</surname> <given-names>H.</given-names></name> <name><surname>Epstein</surname> <given-names>E.</given-names></name></person-group> (<year>1937</year>). <source>Une Forme C&#x00E9;r&#x00E9;brale de La Cholest&#x00E9;rinose G&#x00E9;n&#x00E9;ralis&#x00E9;e</source> Edn. <publisher-name>Masson</publisher-name>. <publisher-loc>Paris</publisher-loc>.</citation></ref>
<ref id="ref142"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Gassen</surname> <given-names>K. L. I.</given-names></name> <name><surname>van der Heijden</surname> <given-names>C. D. C. C.</given-names></name> <name><surname>de Bot</surname> <given-names>S. T.</given-names></name> <name><surname>den Dunnen</surname> <given-names>W. F. A.</given-names></name> <name><surname>van den Berg</surname> <given-names>L. H.</given-names></name> <name><surname>Verschuuren-Bemelmans</surname> <given-names>C. C.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Genotype-phenotype correlations in spastic paraplegia type 7: a study in a large Dutch cohort</article-title>. <source>Brain</source> <volume>135</volume>, <fpage>2994</fpage>&#x2013;<lpage>3004</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/aws224</pub-id></citation></ref>
<ref id="ref143"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Vermeer</surname> <given-names>S.</given-names></name> <name><surname>Warrenburg</surname> <given-names>B. P.</given-names></name> <name><surname>Kamsteeg</surname> <given-names>E. J.</given-names></name> <name><surname>Brais</surname> <given-names>B.</given-names></name> <name><surname>Synofzik</surname> <given-names>M.</given-names></name></person-group> (<year>2020</year>). &#x201C;<article-title>ARSACS</article-title>&#x201D; in <source>GeneReviews&#x00AE;</source>. eds. <person-group person-group-type="editor"><name><surname>Adam</surname> <given-names>M. P.</given-names></name> <name><surname>Feldman</surname> <given-names>J.</given-names></name> <name><surname>Mirzaa</surname> <given-names>G. M.</given-names></name> <etal/></person-group>. (<publisher-loc>Seattle (WA)</publisher-loc>: <publisher-name>University of Washington</publisher-name>)</citation></ref>
<ref id="ref145"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vill</surname> <given-names>K.</given-names></name> <name><surname>M&#x00FC;ller-Felber</surname> <given-names>W.</given-names></name> <name><surname>Gl&#x00E4;ser</surname> <given-names>D.</given-names></name> <name><surname>Kuhn</surname> <given-names>M.</given-names></name> <name><surname>Teusch</surname> <given-names>V.</given-names></name> <name><surname>Schreiber</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>SACS variants are a relevant cause of autosomal recessive hereditary motor and sensory neuropathy</article-title>. <source>Hum. Genet.</source> <volume>137</volume>, <fpage>911</fpage>&#x2013;<lpage>919</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00439-018-1952-6</pub-id></citation></ref>
<ref id="ref146"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walterfang</surname> <given-names>M.</given-names></name> <name><surname>Macfarlane</surname> <given-names>M. D.</given-names></name> <name><surname>Looi</surname> <given-names>J. C. L.</given-names></name> <name><surname>Abel</surname> <given-names>L.</given-names></name> <name><surname>Bowman</surname> <given-names>E.</given-names></name> <name><surname>Fahey</surname> <given-names>M. C.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Pontine-to-midbrain ratio indexes ocular-motor function and illness stage in adult Niemann-pick disease type C</article-title>. <source>Eur. J. Neurol.</source> <volume>19</volume>, <fpage>462</fpage>&#x2013;<lpage>467</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1468-1331.2011.03545.x</pub-id>, PMID: <pub-id pub-id-type="pmid">22329857</pub-id></citation></ref>
<ref id="ref147"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiethoff</surname> <given-names>S.</given-names></name> <name><surname>Ahmad</surname> <given-names>Z.</given-names></name> <name><surname>Ludger</surname> <given-names>S.</given-names></name> <name><surname>Manuel</surname> <given-names>D. F.</given-names></name></person-group> (<year>2012</year>). <article-title>Retinal nerve fibre layer loss in hereditary spastic paraplegias is restricted to complex phenotypes</article-title>. <source>BMC Neurol.</source> <volume>12</volume>:<fpage>143</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2377-12-143</pub-id></citation></ref>
<ref id="ref148"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>L. J. C.</given-names></name> <name><surname>Naviaux</surname> <given-names>R. K.</given-names></name> <name><surname>Brunetti-Pierri</surname> <given-names>N.</given-names></name> <name><surname>Zhang</surname> <given-names>Q.</given-names></name> <name><surname>Schmitt</surname> <given-names>E. S.</given-names></name> <name><surname>Truong</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Molecular and clinical genetics of mitochondrial diseases due to POLG mutations</article-title>. <source>Hum. Mutat.</source> <volume>29</volume>, <fpage>E150</fpage>&#x2013;<lpage>E172</lpage>. doi: <pub-id pub-id-type="doi">10.1002/humu.20824</pub-id>, PMID: <pub-id pub-id-type="pmid">18546365</pub-id></citation></ref>
<ref id="ref149"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname> <given-names>T.</given-names></name> <name><surname>Uchihara</surname> <given-names>T.</given-names></name> <name><surname>Kumagai</surname> <given-names>J.</given-names></name> <name><surname>Shiojiri</surname> <given-names>T.</given-names></name> <name><surname>Pang</surname> <given-names>J. J.</given-names></name> <name><surname>Arita</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2000</year>). <article-title>Postmortem study of ataxia with retinitis Pigmentosa by mutation of the alpha-Tocopherol transfer protein gene</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source> <volume>68</volume>, <fpage>521</fpage>&#x2013;<lpage>525</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp.68.4.521</pub-id>, PMID: <pub-id pub-id-type="pmid">10727494</pub-id></citation></ref>
<ref id="ref150"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zee</surname> <given-names>D. S.</given-names></name> <name><surname>Yee</surname> <given-names>R. D.</given-names></name> <name><surname>Singer</surname> <given-names>H. S.</given-names></name></person-group> (<year>1977</year>). <article-title>Congenital ocular motor apraxia</article-title>. <source>Brain</source> <volume>100</volume>, <fpage>581</fpage>&#x2013;<lpage>599</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/100.3.581</pub-id></citation></ref>
</ref-list>
<sec id="sec11">
<title>Glossary</title>
<table-wrap position="anchor" id="tab4">
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="left" valign="top">ARCAs</td>
<td align="left" valign="top">Autosomal Recessive Cerebellar Ataxias</td>
</tr>
<tr>
<td align="left" valign="top">VOR</td>
<td align="left" valign="top">Vestibulo-ocular reflex</td>
</tr>
<tr>
<td align="left" valign="top">AI</td>
<td align="left" valign="top">Artificial intelligence</td>
</tr>
<tr>
<td align="left" valign="top">OCT</td>
<td align="left" valign="top">Optical Coherence Tomography</td>
</tr>
<tr>
<td align="left" valign="top">RNFL</td>
<td align="left" valign="top">Retinal nerve fiber layer</td>
</tr>
<tr>
<td align="left" valign="top">FRDA</td>
<td align="left" valign="top">Freiderich&#x2019;s ataxia</td>
</tr>
<tr>
<td align="left" valign="top">SPG7</td>
<td align="left" valign="top">Spastic Paraplegia 7</td>
</tr>
<tr>
<td align="left" valign="top">ARSACS</td>
<td align="left" valign="top">Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay</td>
</tr>
<tr>
<td align="left" valign="top">AT</td>
<td align="left" valign="top">Ataxia-Telangiectasia</td>
</tr>
<tr>
<td align="left" valign="top">ATLD</td>
<td align="left" valign="top">Ataxia-telangiectasia like disorder</td>
</tr>
<tr>
<td align="left" valign="top">AOA1</td>
<td align="left" valign="top">Ataxia with oculomotor Apraxia type 1</td>
</tr>
<tr>
<td align="left" valign="top">AOA2</td>
<td align="left" valign="top">Ataxia with Oculomotor Apraxia type 2</td>
</tr>
<tr>
<td align="left" valign="top">SCAN1</td>
<td align="left" valign="top">SpinoCerebellar Ataxia with Neuropathy1</td>
</tr>
<tr>
<td align="left" valign="top">CTX</td>
<td align="left" valign="top">Cerebrotendinous Xanthomatosis</td>
</tr>
<tr>
<td align="left" valign="top">NPC</td>
<td align="left" valign="top">Nieman-Pick disease type C</td>
</tr>
<tr>
<td align="left" valign="top">AVED</td>
<td align="left" valign="top">Ataxia with Vitamin E deficiency</td>
</tr>
<tr>
<td align="left" valign="top">NGS</td>
<td align="left" valign="top">Next-generation sequencing</td>
</tr>
<tr>
<td align="left" valign="top">CA</td>
<td align="left" valign="top">Cerebellar ataxias</td>
</tr>
<tr>
<td align="left" valign="top">COQ10D4</td>
<td align="left" valign="top">Coenzyme Q10 deficiency-4</td>
</tr>
<tr>
<td align="left" valign="top">SWJs</td>
<td align="left" valign="top">Square Wave Jerks</td>
</tr>
<tr>
<td align="left" valign="top">FARS</td>
<td align="left" valign="top">Friederich&#x2019;s Ataxia Taring Scale</td>
</tr>
<tr>
<td align="left" valign="top">SANDO</td>
<td align="left" valign="top">Sensory Ataxic Neuropathy, Disartria and Ophthalmoparesis</td>
</tr>
<tr>
<td align="left" valign="top">MIRAS</td>
<td align="left" valign="top">Mithocondrial recessive Ataxia syndrome</td>
</tr>
<tr>
<td align="left" valign="top">PEO</td>
<td align="left" valign="top">Progressive Esternal Ophthalmoparesis</td>
</tr>
<tr>
<td align="left" valign="top">RFC</td>
<td align="left" valign="top">Replication Factor C</td>
</tr>
<tr>
<td align="left" valign="top">ICARS</td>
<td align="left" valign="top">International Cooperative Ataxia rating Scale</td>
</tr>
<tr>
<td align="left" valign="top">SARA</td>
<td align="left" valign="top">Scale for Assessment and Rating of Ataxia</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</back>
</article>
